0001564590-21-009887 | 10-K | XBRL Viewer

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2020

Commitments And Contingencies Disclosure [Abstract]

Schedule of Outstanding Non-cancelable Purchase Commitments

As of December 31, 2020, we had outstanding non-cancelable purchase commitments related to inventory, supplies, capital expenditures, and other goods or services as follows:

2021		16,542
2022		20
2023		18
	$	16,580

Schedule of Base Salary for Continuing Employment Agreement

Under terms of employment agreements with certain employees, which extend through 2024, we are required to pay each individual a base salary for continuing employment with us as follows:

2021		2,947
2022		1,213
2023		409
2024		—
	$	4,569

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 160,802	$ 75,715
Short-term investments	48,599	80,623
Accounts receivable, net of allowance for doubtful accounts of $3,654 and $2,666	38,835	36,948
Inventories	31,863	23,155
Prepaid expenses	3,860	2,433
Other current assets	4,934	5,676
Total current assets	288,893	224,550
Noncurrent Assets:
Property, plant and equipment, net	51,860	30,339
Operating right-of-use assets, net	4,461	4,996
Finance right-of-use assets, net	1,312	1,951
Intangible assets, net	17,904	14,674
Goodwill	40,351	36,201
Long-term investments	47,718	33,420
Other noncurrent assets	1,973	3,164
Total noncurrent assets	165,579	124,745
TOTAL ASSETS	454,472	349,295
Current Liabilities:
Accounts payable	17,407	9,567
Deferred revenue	4,811	3,713
Accrued expenses	22,227	14,288
Finance lease liability	517	613
Operating lease liability	1,125	1,032
Acquisition-related contingent consideration obligation	402	3,500
Total current liabilities	46,489	32,713
Noncurrent Liabilities:
Finance lease liability	895	1,372
Operating lease liability	3,591	4,206
Acquisition-related contingent consideration obligation	2,049	112
Other noncurrent liabilities	1,682	2,848
Deferred income taxes	1,195	899
Total noncurrent liabilities	9,412	9,437
TOTAL LIABILITIES	55,901	42,150
COMMITMENTS AND CONTINGENCIES (Note 14)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued
Common stock, par value $.000001, 120,000 shares authorized, 71,738 and 61,731 shares issued and outstanding	0	0
Additional paid-in capital	505,123	401,814
Accumulated other comprehensive loss	(9,097)	(12,136)
Accumulated deficit	(97,455)	(82,533)
Total stockholders' equity	398,571	307,145
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 454,472	$ 349,295

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Statement Of Income And Comprehensive Income [Abstract]
NET INCOME (LOSS)	$ (14,922)	$ 16,656	$ 20,396
OTHER COMPREHENSIVE INCOME (LOSS)
Currency translation adjustments	3,273	5,767	(8,003)
Unrealized gain (loss) on marketable securities	(234)	803	(363)
COMPREHENSIVE INCOME (LOSS)	$ (11,883)	$ 23,226	$ 12,030

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

Property, Plant and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Property Plant And Equipment [Abstract]
Depreciation expense	$ 5,514	$ 4,421	$ 3,828

Stockholders' Equity - Schedule of Compensation Expense Recognized in Financial Statements Related to Stock Options (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share Based Compensation Allocation And Classification In Financial Statements [Abstract]
Total compensation cost during the year	$ 892	$ 1,161	$ 2,163
Amounts capitalized into inventory during the year	(466)	(343)	(420)
Amounts recognized in cost of products sold for amounts previously capitalized	360	405	396
Amounts charged against income	$ 786	$ 1,223	$ 2,139

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
OPERATING ACTIVITIES:
Net income (loss)	$ (14,922)	$ 16,656	$ 20,396
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Stock-based compensation	7,139	4,057	15,237
Depreciation and amortization	9,387	7,339	6,451
Other non-cash amortization	327	391	771
Provision for doubtful accounts	941	2,248	(53)
Unrealized foreign currency (gain) loss	269	385	(400)
Interest expense on finance leases	72	36
Deferred income taxes	(392)	(1,457)	(919)
Loss on sale of fixed assets	114	147
Gain on sale of product line	(225)
Gain on sale of business		(10,149)
Change in the estimated fair value of contingent earn-out consideration	(1,099)	(664)
Payment of acquisition related contingent consideration	(496)
Changes in assets and liabilities
Accounts receivable	(2,324)	(2,210)	6,688
Inventories	(8,607)	(1,324)	(3,857)
Prepaid expenses and other assets	(104)	200	(366)
Accounts payable	7,379	(1,537)	208
Deferred revenue	1,051	(297)	2,240
Accrued expenses and other liabilities	7,297	(4,017)	(7,306)
Net cash provided by operating activities	5,807	9,804	39,090
INVESTING ACTIVITIES:
Purchases of investments	(90,137)	(92,173)	(163,763)
Proceeds from maturities and redemptions of investments	107,718	93,491	152,680
Purchases of property and equipment	(26,674)	(9,314)	(6,344)
Purchase of patent and product rights	(2,250)
Acquisition of businesses, net of cash acquired	(3,037)	(23,801)
Proceeds from sale of business		12,000
Other investing activities	351
Net cash used in investing activities	(14,029)	(19,797)	(17,427)
FINANCING ACTIVITIES:
Repayments of loans		(724)
Cash payments for lease liability	(687)	(442)
Proceeds from issuance of common stock, net	95,036
Proceeds from exercise of stock options	3,222	196	1,701
Payment of acquisition related contingent consideration	(3,004)
Repurchase of common stock	(2,088)	(3,712)	(3,592)
Net cash provided by (used in) financing activities	92,479	(4,682)	(1,891)
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	830	1,952	(4,203)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	85,087	(12,723)	15,569
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	75,715	88,438	72,869
CASH AND CASH EQUIVALENTS, END OF PERIOD	$ 160,802	$ 75,715	$ 88,438

Income Taxes - Reconciliation of Statutory United States Federal Income Tax Rate to Domestic Effective Tax Rate (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]
Statutory U.S. federal income tax rate	21.00%	21.00%	21.00%
Deemed repatriation tax			10.90%
GILTI tax		16.90%	22.20%
Nondeductible executive compensation	(0.90%)	0.40%	4.80%
Impact of share-based payment awards	(12.40%)	(5.30%)	0.60%
Tax effect of foreign items	(70.70%)	4.50%	6.80%
State income taxes, net of federal benefit	26.00%	4.00%	2.80%
U.S. and foreign tax credits	34.90%	(1.10%)	(1.00%)
Nondeductible transaction costs	$ (2,800)	$ 1,600
Nondeductible expenses and other	(2.60%)	0.40%	(0.20%)
NOL adjustment due to change in GILTI regulations	308.90%
Change in valuation allowance, federal and state	(624.80%)	(20.50%)	(32.20%)
Effective tax rate	(323.40%)	21.90%	35.70%

Transition Costs - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2018 USD ($)
General and Administrative Expenses [Member]
Transition Costs [Line Items]
Non-cash charges associated with modifications to existing stock grants held by the retiring executives and expenses associated with the onboarding of the Company's new President and CEO	$ 9,602

Sale of Cryosurgical Business - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Aug. 16, 2019
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Gain on sale of business		$ 10,149
Proceeds from sale of business		12,000
Cryosurgical Systems [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Consideration receivable from sale of business			$ 12,000
Gain on sale of business		$ 10,149
Proceeds from sale of business	$ 12,000

Goodwill and Other Intangible Assets

12 Months Ended

Dec. 31, 2020

Goodwill And Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets

7.	GOODWILL AND OTHER INTANGIBLE ASSETS:

The changes in goodwill are as follows:

	December 31,
	2020			2019
Balance as of January 1		36,201			18,521
Goodwill acquired during the year		3,586			16,811
Purchase price adjustment		(126	)		—
Change related to foreign currency translation		690			869
Balance as of December 31	$	40,351		$	36,201

Intangible assets consist of the following:

			December 31, 2020
	Amortization Period (Years)		Gross		Accumulated Amortization			Net

Customer relationships		10	$	14,997	$	(9,685	)	$	5,312
Patents and product rights		5		7,766		(5,792	)		1,974
Developed technology	7-10			16,603		(8,880	)		7,723
Tradename	5-15			5,645		(2,750	)		2,895
			$	45,011	$	(27,107	)	$	17,904

			December 31, 2019
	Amortization Period (Years)		Gross		Accumulated Amortization			Net
Customer relationships		10	$	14,731	$	(8,054	)	$	6,677
Patents and product rights		10		5,400		(5,158	)		242
Developed technology	7-10			12,410		(7,982	)		4,428
Tradename	5-15			5,553		(2,226	)		3,327
			$	38,094	$	(23,420	)	$	14,674

Amortization expense for 2020, 2019, and 2018 was $3,246, $2,522, and $2,623, respectively.

Amortization expense for each of the five succeeding fiscal years and beyond is estimated as follows:

2021		3,291
2022		2,345
2023		2,345
2024		2,302
2025		2,050
Beyond		5,571
	$	17,904

Income Taxes - Components of Income Tax Expense (Benefit) (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Current
Federal	$ 0	$ 0	$ 0
State	(106,000)	1,033,000	155,000
Foreign	11,896,000	5,099,000	12,084,000
Total current income tax expense (benefit)	11,790,000	6,132,000	12,239,000
Deferred
Federal	(20,946,000)	3,568,000	9,200,000
State	(1,053,000)	125,000	1,011,000
Foreign	(410,000)	(697,000)	(919,000)
Total deferred income tax expense (benefit)	(22,409,000)	2,996,000	9,292,000
Decrease in valuation allowance	22,017,000	(4,453,000)	(10,211,000)
Deferred income taxes	(392,000)	(1,457,000)	(919,000)
Total income tax expense	$ 11,398,000	$ 4,675,000	$ 11,320,000

Retirement Plans - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Defined Benefit Plan Disclosure [Line Items]
Employee contributions	$ 4,000
Contributed to plan, net of forfeitures	994,000	$ 754,000	$ 721,000
Value of the assets associated with the plan	2,565,000	3,519,000
Total obligation under plan	2,565,000	3,519,000
RRSP [Member] \| DNA Genotek [Member]
Defined Benefit Plan Disclosure [Line Items]
Employee contributions	4,000
Contributed to plan, net of forfeitures	$ 366,000	$ 184,000	$ 163,000

Business Segment Information - Presentation of Total Long-Lived Assets by Geographic Area (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	$ 51,860	$ 30,339
United States [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	36,897	23,846
Canada [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	10,616	5,697
Other Regions [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	$ 4,347	$ 796

Goodwill and Other Intangible Assets - Schedule of Changes in Goodwill (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Goodwill Roll Forward
Beginning Balance	$ 36,201	$ 18,521
Goodwill acquired during the year	3,586	16,811
Purchase price adjustment	(126)
Change related to foreign currency translation	690	869
Ending Balance	$ 40,351	$ 36,201

Income Taxes - Expiry Details of Federal Net Operating Losses Carryforwards (Detail) $ in Thousands	Dec. 31, 2020 USD ($)
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 136,254
2021 - 2031 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	26,317
2032 - 2037 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	45,072
Non-Expiring [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 64,865

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Principles of Consolidation and Basis of Presentation

The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiaries, DNAG, Diversigen, and Novosanis. All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated.

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the fair value of assets acquired and liabilities assumed for business combinations, the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to accruals, taxes, contingent consideration and performance-based compensation expense, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.

Supplemental Cash Flow Information

In 2020, 2019 and 2018, we paid income taxes of $9,263, $10,611 and $17,126, respectively.

In 2020, 2019 and 2018, we recorded through the consolidated statements of operations an increase (decrease) in our allowance for doubtful accounts of $941, $2,248 and $(53), respectively. We had write-offs of $501, $110 and $11 in 2020, 2019, and 2018, respectively.

As of December 31, 2020, 2019 and 2018, we had accruals for purchases of property and equipment of $802, $660, and $964, respectively.

Investments

We consider all investments in debt securities to be available-for-sale securities. These securities are comprised of guaranteed investment certificates and corporate bonds with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.

We record an allowance for credit loss for our available-for-sale securities when a decline in investment market value is due to credit-related factors. When evaluating an investment for impairment, we review factors such as the severity of the impairment, changes in underlying credit ratings, forecasted recovery, the Company’s intent to sell or the likelihood that it would be required to sell the investment before its anticipated recovery in market value and the probability that the scheduled cash payments will continue to be made. As of December 31, 2020, we determined that the decline in the market value of our available-for-sale investment was not due to credit-related factors and as such no allowance for credit-loss was necessary.

The following is a summary of our available-for-sale securities as of December 31, 2020 and 2019:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
December 31, 2020
Guaranteed investment certificates	$	25,132	$	—	$	—		$	25,132
Corporate bonds		71,533		135		(483	)		71,185
Total available-for-sale securities	$	96,665	$	135	$	(483	)	$	96,317
December 31, 2019
Guaranteed investment certificates	$	24,632	$	—	$	—		$	24,632
Corporate bonds		89,525		271		(385	)		89,411
Total available-for-sale securities	$	114,157	$	271	$	(385	)	$	114,043
At December 31, 2020, maturities of our available- for-sale securities were as follows:
Less than one year	$	48,835	$	114	$	(350	)	$	48,599
Greater than one year	$	47,830	$	21	$	(133	)	$	47,718

Fair Value of Financial Instruments

As of December 31, 2020 and 2019, the carrying values of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their respective fair values based on their short-term nature.

Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

All of our available-for-sale debt securities are measured as Level 2 instruments as of December 31, 2020 and 2019. Our guaranteed investment certificates are measured as Level 1 instruments as of December 31, 2020 and 2019.

Included in cash and cash equivalents at December 31, 2020 and 2019, was $71,489 and $1,624 invested in government money market funds. These funds have investments in government securities and are measured as Level 1 instruments.

We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds. The fair value of the plan assets as of December 31, 2020 and 2019 was $2,565 and $3,519, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in both current assets and other noncurrent assets with the same amounts included in accrued expenses and other noncurrent liabilities in the accompanying consolidated balance sheets.

As further discussed in Note 3, Business Combinations, we have identified our contingent consideration obligations as Level 3 liabilities due to significant inputs that are required to measure the fair value of these obligations.

The following table represents the change in contingent consideration:

Balance as of January 1, 2019	$	—
Addition related to acquisition (initial measurement)		4,350
Change in fair value during the period		(664	)
Currency translation adjustment		(74	)
Balance as of December 31, 2019		3,612
Addition related to acquisition (initial measurement)		3,440
Payments made during the period		(3,500	)
Change in fair value during the period		(1,099	)
Currency translation adjustment		(2	)
Balance as of December 31, 2020	$	2,451

Accounts Receivable

Accounts receivable have been reduced by an estimated allowance for amounts that may become uncollectible in the future. This estimated allowance is based primarily on management’s evaluation of specific balances as they become past due, the financial condition of our customers and our historical experience related to write-offs.

Inventories

Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis, and include the cost of raw materials, labor and overhead. The majority of our inventories are subject to expiration dating, which can be extended in certain circumstances. We continually evaluate quantities on hand and the carrying value of our inventories to determine the need for reserves for excess and obsolete inventories, based on prior experience as well as estimated forecasts of product sales. We reserve for unidentified scrap or spoilage based on historical write-off rates. We also consider items identified through specific identification procedures in assessing the adequacy of our reserve. When factors indicate that impairment has occurred, either a reserve is established against the inventories’ carrying value or the inventories are completely written off, as in the case of lapsing expiration dates.

Property, Plant and Equipment

Property, plant and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of operations.

Intangible Assets

Intangible assets consist of customer relationships, patents and product rights, acquired technology and tradenames. Patents and product rights consist of costs associated with the acquisition of patents, licenses and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of five to fifteen years.

Impairment of Long-Lived Assets

Long-lived assets, which include property and equipment and definite-lived intangible assets, are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. We assess the recoverability of our long-lived assets by determining whether the carrying value of such assets can be recovered through the sum of the undiscounted future cash flows generated from the use and eventual disposition of the asset. If indicators of impairment exist, we measure the amount of such impairment by comparing the carrying value of the assets to the fair value of these assets, which is generally determined based on the present value of the expected future cash flows associated with the use of the assets. Expected future cash flows reflect our assumptions about selling prices, volumes, costs and market conditions over a reasonable period of time.

Goodwill

Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the carrying value of a reporting unit is greater than its fair value, then we would be required to recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, provided the impairment charge does not exceed the total amount of goodwill allocated to the reporting unit.

We performed our annual impairment assessment as of July 31, 2020 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our reporting units is greater than their carrying value. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting units. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs.

Revenue

Product Sales

Product sales. Revenue from product sales is recognized upon transfer of control of a product to a customer based on an amount that reflects the consideration we are entitled to, net of allowances for any discounts or rebates.

We generally do not grant product return rights to our customers, except for warranty returns, return rights on sales of our OraQuick^® In-Home HIV test to the retail trade, and under the terms of a long-term contract with a genomics customer, which was amended in 2020 to remove the return rights provision.

Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.

We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold.

Service Revenues

Service revenues. Service revenues represent microbiome laboratory testing and analytical services. We recognize revenues and satisfy our performance obligation for services rendered.

Arrangements with Multiple-performance Obligations

Arrangements with multiple-performance obligations. In arrangements involving more than one performance obligation, which largely applies to our service revenue stream, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or services is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on their respective relative stand-alone selling price. The estimated selling price of each deliverable is determined using an observable cost plus margin approach. The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred for the related goods or services or when the performance obligation has been satisfied.

Other Revenues

Other revenues. Other revenues consist primarily of royalty income, funding of research and development efforts and cost reimbursements under a charitable support agreement. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Funding and charitable support reimbursements are recorded as the activities are being performed in accordance with the respective agreements.

Deferred Revenue

Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of December 31, 2020 and 2019 included customer prepayments of $3,216 and $1,904, respectively. Deferred revenue as of December 31, 2020 and 2019 also included $1,595 and $1,809, respectively, associated with a long-term contract that has variable pricing based on volume. The average price over the life of contract was determined based on expected revenues and revenue is recognized at that rate when the product is delivered to the customer.

Financing and Payment

Financing and Payment. Our payment terms vary by the type and location of our customer and products or services offered. Payment terms differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation.

For certain products or services and customer types, we may require payment before the products are delivered or services are rendered to the customer.

Practical Expedients and Exemptions

Practical expedients and exemptions. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.

Sales commissions are expensed when incurred if the amortization period is one year or less. These costs are recorded in sales and marketing expense in the consolidated statements of operations. If the amortization period exceeds one year, we defer the cost of the commission and expense it over the life of the related sales contract.

Revenues by Product

Revenues by product. The following table represents total net revenues by product line:

	Year Ended December 31,
	2020		2019		2018
Infectious disease testing	$	54,227	$	58,016	$	56,159
Risk assessment testing		9,374		12,189		12,058
Cryosurgical systems		—		7,054		10,767
Genomics		37,141		56,200		79,754
Microbiome		6,156		7,172		6,690
COVID-19		49,802		—		—
Laboratory services		9,564		6,767		—
Other product revenue		117		675		—
Net product and service revenues		166,381		148,073		165,428
Royalty income		3,432		5,116		9,653
Other non-product revenues		1,908		1,416		6,662
Other revenues		5,340		6,532		16,315
Net revenues	$	171,721	$	154,605	$	181,743

Revenues by Geographic Area

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:

	Years Ended December 31,
	2020		2019		2018
United States	$	130,835	$	107,279	$	136,847
Europe		12,068		11,752		11,062
Other regions		28,818		35,574		33,834
	$	171,721	$	154,605	$	181,743

Customer and Vendor Concentrations

Customer and Vendor Concentrations. One of our customers accounted for 11% of our accounts receivable as of December 31, 2020 and another customer accounted for 19% of our accounts receivable as of December 31, 2019. The same customer accounted for approximately 15% and 24% of our net consolidated revenues for the year ended December 31, 2019 and 2018, respectively. We had no customers that accounted for more than 10% of our consolidated net revenues for the year ended December 31, 2020.

We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the

delivery of our products to our customers. Third-party suppliers also manufacture certain products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.

Business Combinations and Contingent Consideration

Acquired businesses are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. Amounts allocated to contingent consideration are recorded to the balance sheet at the date of acquisition based on their relative fair values. The purchase price allocation requires us to make significant estimates and assumptions, especially at the acquisition date, with respect to intangible assets. Although we believe the assumptions and estimates we have made are reasonable, they are based in part on historical experience and information obtained from the management of the acquired companies and are inherently uncertain.

We account for contingent consideration in accordance with applicable guidance provided within the business combination accounting standard. As part of our consideration for the recent acquisitions, we are contractually obligated to pay certain consideration resulting from the outcome of future events. Therefore, we are required to update our underlying assumptions each reporting period, based on new developments, and record such contingent consideration liabilities at fair value until the contingency is resolved. Changes in the fair value of the contingent consideration liabilities are recognized each reporting period and included in our consolidated statements of operations. Our estimates of fair value are based on assumptions we believe to be reasonable, but the assumptions are uncertain and involve significant judgment by management. Updates to these assumptions could have a significant impact on our results of operations in any given period and any updates to the fair value of the contingent consideration could differ materially from the previous estimates.

Examples of critical estimates used in valuing certain intangible assets and contingent consideration include:


	•		future expected cash flows from sales and acquired developed technologies;


	•		the acquired company's trade name and customer relationships as well as assumptions about the period of time the acquired trade name and customer relationships will continue to be used in the combined company's portfolio;


	•		the probability of meeting the future events; and

•

discount rates used to determine the present value of estimated future cash flows.

These estimates are inherently uncertain and unpredictable, and if different estimates were used the purchase price for the acquisition could be allocated to the acquired assets and liabilities differently from the allocation that we have made. In addition, unanticipated events and circumstances may occur, which may affect the accuracy or validity of such estimates, and if such events occur we may be required to record a charge against the value ascribed to an acquired asset or an increase in the amounts recorded for assumed liabilities.

Research and Development

Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities expenses, overhead expenses, clinical trial and related clinical manufacturing expenses, contract services and other outside expenses. Research and development costs are charged to expense as incurred.

Advertising Expenses

Advertising costs are charged to expense as incurred. During 2020, 2019, and 2018, we incurred $1,126, $468, and $745, respectively, in advertising expenses.

Stock-Based Compensation

We account for stock-based compensation to employees and directors using the fair value method. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. We recognize compensation expense related to performance-based restricted stock units based on

assumptions as to what percentage of each performance target will be achieved. We evaluate these target assumptions on a quarterly basis and adjust compensation expense related to these awards, as appropriate. To satisfy the exercise of options, issuance of restricted stock, or redemption of performance-based restricted stock units, we issue new shares rather than purchase shares in the open market.

Income Taxes

We follow the asset and liability method for accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax basis of assets and liabilities, as well as operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates for the respective taxing jurisdiction that are expected to apply to taxable income in the years in which those temporary differences and operating loss and credit carryforwards are expected to be recovered, settled or utilized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

We assess the realizability of our net deferred tax assets on a quarterly basis. If, after considering all relevant positive and negative evidence, it is more likely than not that some portion or all of the net deferred tax assets will not be realized, we reduce our net deferred tax assets by a valuation allowance. The realization of the net deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of our net operating loss carryforwards.

Foreign Currency Translation

The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.

Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in our consolidated statements of operations in the period in which the change occurs. Net foreign exchange gains (losses) resulting from foreign currency transactions that are included in other income (expense) in our consolidated statements of operations were $(337), $(1,339), and $831 for the years ended December 31, 2020, 2019, and 2018, respectively.

Earnings (Loss) Per Share

Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed in a manner similar to basic earnings (loss) per share except that the weighted-average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options, unvested restricted stock or performance stock units, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares and performance stock units were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period. Basic and dilutive computations of net loss per share are the same in periods in which a net loss exists as the dilutive effects of excluded items would be anti-dilutive.

The computations of basic and diluted earnings (loss) per share are as follows:

	Year ended December 31,
	2020			2019		2018
Net income (loss)	$	(14,922	)	$	16,656	$	20,396
Weighted average shares of common stock outstanding:
Basic		67,505			61,675		61,112
Dilutive effect of stock options, restricted stock, and performance stock units		—			495		1,420
Diluted		67,505			62,170		62,532
Earnings (loss) per share:
Basic	$	(0.22	)	$	0.27	$	0.33
Diluted	$	(0.22	)	$	0.27	$	0.33

For the year ended December 31, 2020, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 984 shares were excluded from the computation of diluted loss per share.

For the years ended December 31, 2019, and 2018, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 768 and 291 shares, respectively, were excluded from the computation of diluted earnings per share as their inclusion would have been anti-dilutive.

Accumulated Other Comprehensive Loss

We classify items of other comprehensive income (loss) by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our consolidated balance sheets.

We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and we have defined the Euro as the functional currency of our Belgian subsidiary, Novosanis. The results of operations are translated into U.S. dollars, which is the reporting currency of the Company. Accumulated other comprehensive loss at December 31, 2020 consists of $8,749 of currency translation adjustments and $348 of net unrealized losses on marketable securities, which represents the fair market value adjustment for our investments portfolio. Accumulated other comprehensive loss at December 31, 2019 consists of $12,022 of currency translation adjustments and $114 of net unrealized losses on marketable securities.

Recent Accounting Pronouncements

In June 2016, the FASB issued guidance on the measurement of credit losses, which requires measurement and recognition of expected credit losses for financial assets, including trade receivables and capital lease receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The method to determine a loss requires a credit loss to be recognized when it is probable. We adopted this guidance in the first quarter of 2020 and the impact of the adoption was not material to the Company's consolidated financial statements as credit losses are not expected to be significant based on historical collection trends, the financial condition of payment partners, and external market factors. The Company will continue to actively monitor the impact of the coronavirus (COVID-19) pandemic on expected credit losses. In addition, the new guidance requires us to record an allowance for credit loss when a decline in investment market value is due to credit-related factors. As of January 1, 2020, there was no material decline in the market value of available-for-sale investments due to credit-related factors.

In February 2018, the FASB issued guidance allowing a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the U.S. Tax Cuts and Jobs Act. If elected, the reclassification can be applied in either the period of adoption or retrospectively to the period of the enactment of the U.S. Tax Cuts and Jobs Act (i.e., our first quarter of fiscal year 2018). We adopted this guidance in the first quarter of 2020 and the impact of the adoption was not material to the Company's consolidated financial statements.

In August 2018, the FASB issued guidance related to fair value measurement disclosures. This guidance removes the requirement to disclose the amount of and reasons for transfers between Levels 1 and 2 of the fair value hierarchy, the policy for determining that a transfer has occurred, and valuation processes for Level 3 fair value measurements. Additionally, this guidance modifies the disclosures related to the measurement uncertainty for recurring Level 3 fair value measurements (by removing the requirement to disclose sensitivity to future changes) and the timing of liquidation of invested assets (by removing the timing requirement in certain instances). The guidance also requires new disclosures for Level 3 financial assets and liabilities, including the amount and location of unrealized gains and losses recognized in other comprehensive income(loss) and additional information related to significant unobservable inputs used in determining Level 3 fair value measurements. We adopted this guidance in the first quarter of 2020 and the impact of the adoption was not material to the Company's consolidated financial statements.

Business Combinations - Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Jul. 22, 2020	Dec. 31, 2019	Nov. 08, 2019	Jan. 04, 2019	Dec. 31, 2018
Assets Acquired
Goodwill	$ 40,351		$ 36,201			$ 18,521
UrSure Inc [Member]
Assets Acquired
Accounts receivable		$ 285
Other current assets		24
Other assets		6
Intangibles		3,600
Goodwill		3,586
Total assets acquired		7,501
Liabilities Assumed
Current liabilities		335
Deferred tax liability		689
Total liabilities assumed		1,024
Net Assets Acquired		6,477
Estimated fair value of contingent consideration	(2,451)	(3,440)
Net Cash Paid		$ 3,037
Diversigen, Inc. [Member]
Assets Acquired
Accounts receivable				$ 1,234
Other current assets				45
Intangibles				3,560
Goodwill				6,317
Total assets acquired				13,072
Property, plant, and equipment, net				1,916
Liabilities Assumed
Current liabilities				1,123
Deferred tax liability				598
Total liabilities assumed				2,614
Other long-term liabilities				893
Net Assets Acquired				10,458
Net Cash Paid				$ 10,458
Corebiome Inc. and Novosanis NV [Member]
Assets Acquired
Accounts receivable					$ 791
Other current assets					82
Other assets					5
Intangibles					8,400
Goodwill					10,368
Total assets acquired					20,370
Property, plant, and equipment, net					414
Inventories					310
Liabilities Assumed
Current liabilities					1,180
Deferred tax liability					819
Total liabilities assumed					2,803
Other long-term liabilities					74
Notes payable, short-term					730
Net Assets Acquired					17,567
Estimated fair value of contingent consideration	$ 0		$ (3,612)		(4,350)
Net Cash Paid					$ 13,217

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Foreign income tax expense	$ 12,185,000	$ 4,607,000	$ 11,165,000
U.S. federal income tax benefits	0	0	0
Gross unrecognized tax benefits	$ 1,172,000	$ 1,308,000	$ 1,676,000	$ 1,663,000

Retirement Plans

12 Months Ended

Dec. 31, 2020

Compensation And Retirement Disclosure [Abstract]

Retirement Plans

15.	RETIREMENT PLANS:

Substantially all of our U.S. employees are eligible to participate in the OraSure Technologies, Inc. 401(k) Plan (the “401(k) Plan”). The 401(k) Plan permits voluntary employee contributions to be excluded from an employee’s current taxable income under provisions of Internal Revenue Code Section 401(k) and the regulations thereunder. The 401(k) Plan also provides for us to match employee contributions up to $4 per year. We contributed $994, $754 and $721 to the 401(k) Plan, net of forfeitures, in 2020, 2019, and 2018, respectively.

In addition to our 401(k) plan, we offer a nonqualified deferred compensation plan to permit eligible directors and highly compensated employees of the Company to defer receipt and taxation of their compensation each year. We also may make discretionary contributions to the accounts of the participating employees in any amount either in cash or stock. Participants in the plan may not purchase OraSure stock as an investment vehicle. As of December 31, 2020 and 2019, the value of the assets associated with this plan was $2,565 and $3,519, respectively, and is included in current assets and other assets in our consolidated balance sheets. Our obligation related to the deferred compensation plan is included in accrued expenses and other liabilities in our consolidated balance sheets. As of December 31, 2020 and 2019, our total obligation under this plan was $2,565 and $3,519, respectively.

Substantially all regular full-time Canadian employees are eligible to participate in the DNA Genotek Registered Retirement Savings Plan (the “RRSP”). The RRSP permits voluntary employee contributions to be excluded from an employee’s current taxable income and receive tax preferred treatment with Revenue Canada. The RRSP also provides for DNAG to match employee contributions up to $4 per year. We contributed $366, $184 and $163 to the RRSP in 2020, 2019, and 2018, respectively.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

+ Details

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Inventory Net [Abstract]
Raw materials	$ 15,425	$ 14,168
Work in process	2,572	643
Finished goods	13,866	8,344
Inventories	$ 31,863	$ 23,155

Goodwill and Other Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Goodwill And Intangible Assets Disclosure [Abstract]
Amortization expense	$ 3,246	$ 2,522	$ 2,623

Goodwill and Other Intangible Assets - Summary of Amortization Expense (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Finite Lived Intangible Assets Future Amortization Expense [Abstract]
2021	$ 3,291
2022	2,345
2023	2,345
2024	2,302
2025	2,050
Beyond	5,571
Intangible Assets, Net	$ 17,904	$ 14,674

Business Combinations - Summary of Identifiable Intangible Assets Subject to Amortization on Straight-line Basis and Being Amortized over Estimated Useful Lives (Detail) - USD ($) $ in Thousands			12 Months Ended
	Nov. 08, 2019	Jan. 04, 2019	Dec. 31, 2020	Dec. 31, 2019
Customer Relationships [Member]
Business Acquisition [Line Items]
Acquired intangibles, Estimated Useful Life			10 years	10 years
Diversigen, Inc. [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount	$ 3,560
Diversigen, Inc. [Member] \| Customer Relationships [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount	$ 2,900
Acquired intangibles, Estimated Useful Life	10 years
Diversigen, Inc. [Member] \| Tradenames [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount	$ 660
Acquired intangibles, Estimated Useful Life	9 years
Corebiome Inc. and Novosanis NV [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount		$ 8,400
Corebiome Inc. and Novosanis NV [Member] \| Customer Relationships [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount		$ 2,200
Acquired intangibles, Estimated Useful Life		10 years
Corebiome Inc. and Novosanis NV [Member] \| Tradenames [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount		$ 1,200
Acquired intangibles, Estimated Useful Life		8 years 4 months 2 days
Corebiome Inc. and Novosanis NV [Member] \| Developed Technology [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount		$ 5,000
Acquired intangibles, Estimated Useful Life		10 years

Leases - Summary of Lease Term and Discount Rate (Detail)	Dec. 31, 2020
Weighted Average Remaining Lease Term
Weighted-average remaining lease term—operating leases	4 years 5 months 12 days
Weighted-average remaining lease term—finance leases	2 years 8 months 1 day
Weighted Average Discount Rate
Weighted-average discount rate—operating leases	4.28%
Weighted-average discount rate—finance leases	4.35%

Stockholders' Equity - Weighted-Average Assumptions for Fair Value Measurement (Detail)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]
Risk-free interest rate	1.33%	2.52%	2.60%
Expected dividend yield	0.00%	0.00%	0.00%
Expected stock price volatility	42.00%	41.00%	43.00%
Expected life of stock options (in years)	5 years	5 years	6 years

Income Taxes

12 Months Ended

Dec. 31, 2020

Income Tax Disclosure [Abstract]

Income Taxes

10.	INCOME TAXES:

Income (loss) before income tax expense consists of the following:

	Years Ended December 31,
	2020			2019		2018
United States	$	(47,995	)	$	3,106	$	(11,728	)
Foreign		44,471			18,225		43,444
	$	(3,524	)	$	21,331	$	31,716

The components of income tax expense are as follows:

	Years Ended December 31,
	2020			2019			2018
Current
Federal	$	—		$	—		$	—
State		(106	)		1,033			155
Foreign		11,896			5,099			12,084
		11,790			6,132			12,239
Deferred
Federal		(20,946	)		3,568			9,200
State		(1,053	)		125			1,011
Foreign		(410	)		(697	)		(919	)
		(22,409	)		2,996			9,292
Decrease in valuation allowance		22,017			(4,453	)		(10,211	)
		(392	)		(1,457	)		(919	)
Total income tax expense	$	11,398		$	4,675		$	11,320

For the years ended December 31, 2020, 2019, and 2018 we recorded foreign income tax expense of $12,185, $4,607, and $11,165, respectively.

The Tax Cuts and Jobs Act imposed a U.S. tax on GILTI that is earned by certain foreign affiliates owned by a U.S. shareholder effective in 2018. GILTI is generally intended to impose tax on the earnings of a foreign corporation that are deemed to exceed a certain threshold return relative to the underlying tangible property. The GILTI computation for 2018 was completed and is reflected in the 2018 income tax provision. The Company has made a policy election related to its treatment of GILTI and will treat it as a current period expense in the reporting period in which the tax is incurred.

Final GILTI regulations were released in 2020. Among the changes was a GILTI “High-Tax Exception,” which allows foreign income deemed taxed at a sufficient effective rate to be excluded from a US owner’s GILTI income. All foreign income in 2020 fell under this exception. It is expected that foreign income will continue to qualify for the exception in future years.

A reconciliation of the statutory United States federal income tax rate to our effective tax rate for each of the years ended December 31, 2020, 2019, and 2018 is as follows:

	2020				2019				2018
Statutory U.S. federal income tax rate		21.0		%		21.0		%		21.0		%
Deemed repatriation tax		—				—				10.9
GILTI tax		—				16.9				22.2
Nondeductible executive compensation		(0.9	)			0.4				4.8
Impact of share-based payment awards		(12.4	)			(5.3	)			0.6
Tax effect of foreign items		(70.7	)			4.5				6.8
State income taxes, net of federal benefit		26.0				4.0				2.8
U.S. and foreign tax credits		34.9				(1.1	)			(1.0	)
Nondeductible transaction costs		(2.8	)			1.6				—
Nondeductible expenses and other		(2.6	)			0.4				(0.2	)
NOL adjustment due to change in GILTI regulations		308.9				—				—
Change in valuation allowance, federal and state		(624.8	)			(20.5	)			(32.2	)
Effective tax rate		(323.4	)	%		21.9		%		35.7		%

Deferred income taxes reflect the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting purposes and tax purposes, and net operating loss and tax credit carryforwards. Significant components of our deferred tax assets (liabilities) as of December 31, 2020 and 2019 are as follows:

	2020			2019
Deferred tax assets (liabilities):
Net operating loss carryforwards	$	31,701		$	9,897
Inventories		1,593			2,002
Capitalized research and development costs		746			1,183
Accruals and reserves currently not deductible		3,200			2,272
Acquired intangible assets		(3,870	)		(3,525	)
Depreciation and amortization		(2,695	)		(1,999	)
Stock-based compensation		1,354			1,777
Tax credit carryforwards		3,354			2,055
Net deferred tax asset		35,383			13,662
Valuation allowance		(36,578	)		(14,561	)
Net deferred tax liability	$	(1,195	)	$	(899	)

In assessing the realizability of our deferred tax asset, we consider all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent upon several factors, including the generation of sufficient taxable income prior to the expiration of the NOL carryforwards. In 2008, we established a full valuation allowance against our U.S. deferred tax asset, and management believes the full valuation allowance is still appropriate as of December 31, 2020 and 2019 since the facts and circumstances necessitating the allowance have not changed. As a result, no U.S. federal income tax benefit was recorded for the years ended December 31, 2020, 2019, or 2018.

Our Federal NOL carryforwards expire as follows:

Year of Expiration	NOLs
2021 - 2031	$	26,317
2032 - 2037	$	45,072
Non-Expiring		64,865
	$	136,254

The Tax Reform Act of 1986 contains provisions under Internal Revenue Code (“IRC”) Section 382 that limit the annual amount of federal and state NOL carryforwards that can be used in any given year in the event a significant change in ownership. We do not believe that there is a Section 382 limitation that will impair our future ability to utilize NOLs to offset our future taxable income. We

continue to review ownership changes on an annual basis and we do not believe we have had a subsequent ownership change that would impact the NOLs.

Effective January 1, 2018, there is a transition to a participation exemption system whereby distributions from foreign subsidiaries to U.S. shareholders are generally exempt from taxation. Our intention is to continue to permanently reinvest the historical undistributed earnings of our foreign subsidiary to the extent that we will not incur any additional tax expense associated with foreign withholding or other local tax expense on the future cash transfers. As such, deferred taxes have not been recorded on the unremitted earnings of the foreign subsidiary.

As of December 31, 2020, our gross unrecognized tax benefits totaled $1,172, and based upon the valuation allowance for our U.S. operations, the recognition of any tax benefit would not impact our effective tax rate. We record interest and penalties related to unrecognized tax benefits as a component of income tax expense. Interest and penalties were immaterial in 2020, 2019 and 2018. As a result of our net operating loss carryforward position, we are subject to audit by the Internal Revenue Service since our inception, as well as by several state jurisdictions for the years ended September 30, 1998 through December 31, 2020.

A reconciliation of our unrecognized tax benefits is as follows:

	2020			2019			2018
Balance as of January 1	$	1,308		$	1,676		$	1,663
Additions for tax positions of prior periods		1			4			44
Reductions for tax positions of prior periods		(137	)		(372	)		(31	)
Balance as of December 31	$	1,172		$	1,308		$	1,676

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Commitments and Contingencies - Schedule of Outstanding Non-cancelable Purchase Commitments (Detail) $ in Thousands	Dec. 31, 2020 USD ($)
Purchase Obligation Fiscal Year Maturity [Abstract]
2021	$ 16,542
2022	20
2023	18
Total	$ 16,580

Business Combinations - Summary of Unaudited Pro Forma Financial Information (Detail) - CoreBiome Inc. Diversign Novosanis NV and UrSure [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Revenue	$ 172,563	$ 159,632	$ 190,487
Net income	$ (14,937)	$ 16,261	$ 19,448
Net income per share, basic	$ (0.22)	$ 0.26	$ 0.32
Net income per share, diluted	$ (0.22)	$ 0.26	$ 0.31

Inventories

12 Months Ended

Dec. 31, 2020

Inventory Disclosure [Abstract]

Inventories

5.	INVENTORIES:

	December 31,
	2020		2019
Raw materials	$	15,425	$	14,168
Work in process		2,572		643
Finished goods		13,866		8,344
	$	31,863	$	23,155

Business Segment Information - Summary of Operating Segment and Asset Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Segment Reporting Information [Line Items]
Net revenues	$ 171,721	$ 154,605	$ 181,743
Operating income (loss)	(5,177)	18,611	28,429
Depreciation and amortization	9,387	7,339	7,222
Capital expenditures	26,674	9,314	6,344
Total assets	454,472	349,295
Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenues	65,240	78,225	85,635
Operating income (loss)	(43,156)	154	(15,188)
Depreciation and amortization	3,345	3,039	3,755
Capital expenditures	17,860	6,073	4,893
Total assets	242,613	163,943
Molecular Solutions [Member]
Segment Reporting Information [Line Items]
Net revenues	106,481	76,380	96,108
Operating income (loss)	37,979	18,457	43,617
Depreciation and amortization	6,042	4,300	3,467
Capital expenditures	8,814	3,241	$ 1,451
Total assets	$ 211,859	$ 185,352

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

+ Details

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Business Segment Information

12 Months Ended

Dec. 31, 2020

Segment Reporting [Abstract]

Business Segment Information

13.	BUSINESS SEGMENT INFORMATION:

Our business consists of two segments: our “Diagnostics” business, which was previously named “OSUR”, primarily consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using our proprietary technologies, other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our Diagnostics segment includes the financial results of UrSure. Our “Molecular Solutions” business, which was previously named “DNAG,” consists of the development, manufacture, marketing and sale of specimen collection kits that are used to collect, stabilize, transport and store samples of genetic material for molecular testing. Our collection kits are also used for the collection of first-void urine for liquid biopsy in the prostate and bladder cancer markets; and in the sexually transmitted infection screening market. In addition, our Molecular Solutions business provides microbiome laboratory services that accelerate research and discovery for customers in the pharmaceutical, agricultural, and academic research markets. Financial results of Diversigen, CoreBiome and Novosanis are included in our Molecular Solutions segment. Our cryosurgical systems business was included in our Diagnostics segment and the impact of the sale of that business in August 2019 is reflected in the results presented below.

We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income. We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues and inter-segment expenses have been eliminated.

Operating income (loss) for the year ended December 31, 2018 has been modified to conform to the classification of the intercompany service fee presentation for 2019. Beginning with the first quarter of 2019, we have included the fees for intercompany services in our segment operating income (loss) in order to more accurately reflect the results of each segment.

The following table summarizes operating segment information for the years ended December 31, 2020, 2019, and 2018, and asset information as of December 31, 2020 and 2019:

	Years Ended December 31,
	2020			2019		2018
Net revenues:
Diagnostics	$	65,240		$	78,225	$	85,635
Molecular Solutions		106,481			76,380		96,108
Total	$	171,721		$	154,605	$	181,743
Operating income (loss):
Diagnostics	$	(43,156	)	$	154	$	(15,188	)
Molecular Solutions		37,979			18,457		43,617
Total	$	(5,177	)	$	18,611	$	28,429
Depreciation and amortization:
Diagnostics	$	3,345		$	3,039	$	3,755
Molecular Solutions		6,042			4,300		3,467
Total	$	9,387		$	7,339	$	7,222
Capital expenditures:
Diagnostics	$	17,860		$	6,073	$	4,893
Molecular Solutions		8,814			3,241		1,451
Total	$	26,674		$	9,314	$	6,344

	December 31,
	2020		2019
Total assets:
Diagnostics	$	242,613	$	163,943
Molecular Solutions		211,859		185,352
Total	$	454,472	$	349,295

The following table represents total long-lived assets by geographic area:

	December 31,
	2020		2019
United States	$	36,897	$	23,846
Canada		10,616		5,697
Other regions		4,347		796
	$	51,860	$	30,339

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Property, Plant and Equipment

12 Months Ended

Dec. 31, 2020

Property Plant And Equipment [Abstract]

Property, Plant and Equipment

6.	PROPERTY, PLANT AND EQUIPMENT:

	December 31,
	2020			2019
Land	$	1,118		$	1,118
Buildings and improvements		26,480			23,231
Machinery and equipment		36,878			33,568
Computer equipment and software		13,024			11,590
Furniture and fixtures		3,545			2,791
Construction in progress		24,419			4,923
		105,464			77,221
Less accumulated depreciation		(53,604	)		(46,882	)
	$	51,860		$	30,339

Depreciation expense was $5,514, $4,421, and $3,828 for 2020, 2019, and 2018, respectively.

Stockholders' Equity - Summary of Restricted Stock Award and Restricted Stock Units Activity Under Stock Plan (Detail) - Restricted Stock Award and Restricted Stock Units [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2020 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Issued and unvested, Beginning Balance \| shares	464
Shares, Granted \| shares	561
Shares, Vested \| shares	(342)
Shares, Forfeited \| shares	(24)
Shares, Issued and unvested, Ending Balance \| shares	659
Weighted-Average Grant Date Fair Value, Issued and unvested, Beginning Balance \| $ / shares	$ 12.86
Shares, Issued and expected to vest \| shares	659
Weighted-Average Grant Date Fair Value, Granted \| $ / shares	$ 8.35
Weighted-Average Grant Date Fair Value, Vested \| $ / shares	11.14
Weighted-Average Grant Date Fair Value, Forfeited \| $ / shares	11.90
Weighted-Average Grant Date Fair Value, Issued and unvested, Ending Balance \| $ / shares	9.95
Weighted-Average Grant Date Fair Value, Issued and expected to vest \| $ / shares	$ 9.95

Goodwill and Other Intangible Assets - Summary of Intangible Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 45,011	$ 38,094
Intangible Assets, Accumulated Amortization	(27,107)	(23,420)
Intangible Assets, Net	$ 17,904	$ 14,674
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	5 years
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	15 years
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	10 years	10 years
Intangible Assets, Gross	$ 14,997	$ 14,731
Intangible Assets, Accumulated Amortization	(9,685)	(8,054)
Intangible Assets, Net	$ 5,312	$ 6,677
Patents and Product Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	5 years	10 years
Intangible Assets, Gross	$ 7,766	$ 5,400
Intangible Assets, Accumulated Amortization	(5,792)	(5,158)
Intangible Assets, Net	1,974	242
Developed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	16,603	12,410
Intangible Assets, Accumulated Amortization	(8,880)	(7,982)
Intangible Assets, Net	$ 7,723	$ 4,428
Developed Technology [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	7 years	7 years
Developed Technology [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	10 years	10 years
Tradename [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 5,645	$ 5,553
Intangible Assets, Accumulated Amortization	(2,750)	(2,226)
Intangible Assets, Net	$ 2,895	$ 3,327
Tradename [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	5 years	5 years
Tradename [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	15 years	15 years

Summary of Significant Accounting Policies - Summary of Change in Contingent Consideration (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Business Combination Contingent Consideration Arrangements [Abstract]
Beginning Balance	$ 3,612
Addition related to acquisition (initial measurement)	3,440	$ 4,350
Payments made during the period	(3,500)
Change in the estimated fair value of acquisition-related contingent consideration	(1,099)	(664)
Currency translation adjustment	(2)	(74)
Ending Balance	$ 2,451	$ 3,612

Business Segment Information (Tables)

12 Months Ended

Dec. 31, 2020

Segment Reporting [Abstract]

Summary of Operating Segment and Asset Information

The following table summarizes operating segment information for the years ended December 31, 2020, 2019, and 2018, and asset information as of December 31, 2020 and 2019:

	Years Ended December 31,
	2020			2019		2018
Net revenues:
Diagnostics	$	65,240		$	78,225	$	85,635
Molecular Solutions		106,481			76,380		96,108
Total	$	171,721		$	154,605	$	181,743
Operating income (loss):
Diagnostics	$	(43,156	)	$	154	$	(15,188	)
Molecular Solutions		37,979			18,457		43,617
Total	$	(5,177	)	$	18,611	$	28,429
Depreciation and amortization:
Diagnostics	$	3,345		$	3,039	$	3,755
Molecular Solutions		6,042			4,300		3,467
Total	$	9,387		$	7,339	$	7,222
Capital expenditures:
Diagnostics	$	17,860		$	6,073	$	4,893
Molecular Solutions		8,814			3,241		1,451
Total	$	26,674		$	9,314	$	6,344

	December 31,
	2020		2019
Total assets:
Diagnostics	$	242,613	$	163,943
Molecular Solutions		211,859		185,352
Total	$	454,472	$	349,295

Presentation of Total Long-Lived Assets by Geographic Area

The following table represents total long-lived assets by geographic area:

	December 31,
	2020		2019
United States	$	36,897	$	23,846
Canada		10,616		5,697
Other regions		4,347		796
	$	51,860	$	30,339

Commitments and Contingencies - Schedule of Base Salary for Continuing Employment Agreement (Detail) - Employment Agreements [Member] $ in Thousands	Dec. 31, 2020 USD ($)
Contractual Obligation Fiscal Year Maturity [Line Items]
2021	$ 2,947
2022	1,213
2023	409
Total	$ 4,569

Summary of Significant Accounting Policies - Summary of Total Net Revenues by Geographic Area (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disaggregation Of Revenue [Line Items]
Net revenues	$ 171,721	$ 154,605	$ 181,743
United States [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	130,835	107,279	136,847
Europe [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	12,068	11,752	11,062
Other Regions [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	$ 28,818	$ 35,574	$ 33,834

- Definition

+ References

+ Details

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2020	Feb. 22, 2021	Jun. 30, 2020
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Trading Symbol	OSUR
Entity Registrant Name	ORASURE TECHNOLOGIES, INC
Entity Central Index Key	0001116463
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Entity File Number	001-16537
Entity Tax Identification Number	36-4370966
Entity Address, Address Line One	220 East First Street
Entity Address, City or Town	Bethlehem
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	18015
City Area Code	610
Local Phone Number	882-1820
Entity Emerging Growth Company	false
Entity Small Business	false
Document Annual Report	true
ICFR Auditor Attestation Flag	true
Title of 12(b) Security	Common Stock, $0.000001 par value per share
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Transition Report	false
Entity Interactive Data Current	Yes
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding		71,945,502
Entity Public Float			$ 829,039,107
Documents Incorporated by Reference	Documents Incorporated by Reference: Portions of the Registrant’s Definitive Proxy Statement for the 2021 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report.

Leases (Tables)

12 Months Ended

Dec. 31, 2020

Lessee Disclosure [Abstract]

Summary of Components of Lease Expense

The components of lease expense are as follows:

	Year ended		Year ended
	December 31, 2020		December 31, 2019
Operating Lease Cost	$	1,291	$	964
Finance Lease Cost
Amortization of right-of use assets		627		410
Interest on lease liabilities		72		36
Total Finance Lease Cost	$	699	$	446

Summary of Supplemental Cash Flow Information Related to Leases

Supplemental cash flow information related to leases is as follows:

	Year ended		Year ended
	December 31, 2020		December 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	1,280	$	937
Operating cash flows from financing leases		72		33
Financing cash flows from financing leases		687		442
Non-cash activity
Right-of-use assets obtained in exchange for operating lease obligations		498		1,829
Right-of-use assets obtained in exchange for finance lease obligations		46		2,069

Summary of Supplemental Balance Sheet Information Related to Leases

Supplemental balance sheet information related to leases is as follows:

	December 31, 2020		December 31, 2019
Operating Leases
Right-of-use assets	$	4,461	$	4,996
Current lease liabilities		1,125		1,032
Non-current lease liabilities		3,591		4,206
Total operating lease liabilities	$	4,716	$	5,238

Finance Leases
Right-of-use assets	$	1,312	$	1,951
Current lease liabilities		517		613
Non-current lease liabilities		895		1,372
Total finance lease liabilities	$	1,412	$	1,985

Summary of Lease Term and Discount Rate

Weighted Average Remaining Lease Term
Weighted-average remaining lease term—operating leases	4.45
Weighted-average remaining lease term—finance leases	2.67

Weighted Average Discount Rate
Weighted-average discount rate—operating leases	4.28	%
Weighted-average discount rate—finance leases	4.35	%

Schedule of Minimum Lease Payments by Period Expected

	Finance			Operating
2021		566			1,332
2022		566			1,315
2023		337			874
2024		25			894
2025		4			520
Thereafter		-			325
Total Minimum Lease Payments		1,498			5,260
Less: imputed interest		(86	)		(544	)
Present Value of Lease Liabilities	$	1,412		$	4,716

Transition Costs

12 Months Ended

Dec. 31, 2020

Transition Costs [Abstract]

Transition Costs

12.	TRANSITION COSTS

In January 2018, we announced the retirement of our President and CEO and our CFO and Chief Operating Officer. Stephen S. Tang, Ph.D., who served as Chairman of the Board of Directors (the “Board”), was appointed as the Company’s new President and CEO, effective as of April 1, 2018. Dr. Tang replaced Douglas A. Michels, who retired as President and CEO, and as a member of the Board, on March 31, 2018. In addition, Roberto Cuca was appointed as the Company’s new CFO, effective June 8, 2018. Mr. Cuca replaced Ronald H. Spair, our former CFO and Chief Operating Officer, who retired on that same date. Charges associated with these transitions were $9,602 during 2018 and are included in general and administrative expenses in the consolidated statement of income. These charges primarily reflect non-cash charges associated with modifications to existing stock grants held by the retiring executives and expenses associated with the onboarding of the Company’s new President and CEO.

Stockholders' Equity - Summary of Performance Based Restricted Stock Unit Award Activity Under Stock Plan (Detail) - Performance Based Restricted Stock Unit [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2020 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Issued and unvested, Beginning Balance	525
Shares, Granted	368
Performance adjustment	104
Shares, Vested	(311)
Shares, Forfeited	(35)
Shares, Issued and unvested, Ending Balance	651
Shares, Issued and expected to vest	651
Weighted-Average Grant Date Fair Value, Issued and unvested, Beginning Balance \| $ / shares	$ 12.52
Weighted-Average Grant Date Fair Value, Granted \| $ / shares	7.57
Weighted-Average Grant Date Fair Value, Vested \| $ / shares	8.87
Weighted-Average Grant Date Fair Value, Forfeited \| $ / shares	13.87
Weighted-Average Grant Date Fair Value, Issued and unvested, Ending Balance \| $ / shares	11.30
Weighted-Average Grant Date Fair Value, Issued and expected to vest \| $ / shares	$ 11.30

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts	$ 3,654	$ 2,666
Preferred stock, par value	$ 0.000001	$ 0.000001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.000001	$ 0.000001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	71,738,000	61,731,000
Common stock, shares outstanding	71,738,000	61,731,000

Consolidated Statements of Stockholders' Equity (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2020 USD ($)
Statement Of Stockholders Equity [Abstract]
Issuance of common stock in connection with public offering, net of commissions and expenses	$ 6,200

Summary of Significant Accounting Policies - Summary of Available-for-sale Securities (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 96,665	$ 114,157
Gross Unrealized Gains	135	271
Gross Unrealized Losses	(483)	(385)
Fair Value	96,317	114,043
Guaranteed Investment Certificates [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	25,132	24,632
Gross Unrealized Gains	0	0
Fair Value	25,132	24,632
Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	71,533	89,525
Gross Unrealized Gains	135	271
Gross Unrealized Losses	(483)	(385)
Fair Value	71,185	$ 89,411
Less Than One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	48,835
Gross Unrealized Gains	114
Gross Unrealized Losses	(350)
Fair Value	48,599
Greater Than One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	47,830
Gross Unrealized Gains	21
Gross Unrealized Losses	(133)
Fair Value	$ 47,718

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Summary of Available-for-sale Securities

The following is a summary of our available-for-sale securities as of December 31, 2020 and 2019:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
December 31, 2020
Guaranteed investment certificates	$	25,132	$	—	$	—		$	25,132
Corporate bonds		71,533		135		(483	)		71,185
Total available-for-sale securities	$	96,665	$	135	$	(483	)	$	96,317
December 31, 2019
Guaranteed investment certificates	$	24,632	$	—	$	—		$	24,632
Corporate bonds		89,525		271		(385	)		89,411
Total available-for-sale securities	$	114,157	$	271	$	(385	)	$	114,043
At December 31, 2020, maturities of our available- for-sale securities were as follows:
Less than one year	$	48,835	$	114	$	(350	)	$	48,599
Greater than one year	$	47,830	$	21	$	(133	)	$	47,718

Summary of Change in Contingent Consideration

The following table represents the change in contingent consideration:

Balance as of January 1, 2019	$	—
Addition related to acquisition (initial measurement)		4,350
Change in fair value during the period		(664	)
Currency translation adjustment		(74	)
Balance as of December 31, 2019		3,612
Addition related to acquisition (initial measurement)		3,440
Payments made during the period		(3,500	)
Change in fair value during the period		(1,099	)
Currency translation adjustment		(2	)
Balance as of December 31, 2020	$	2,451

Disaggregation of Revenue by Product and Geographic Area

Revenues by product. The following table represents total net revenues by product line:

	Year Ended December 31,
	2020		2019		2018
Infectious disease testing	$	54,227	$	58,016	$	56,159
Risk assessment testing		9,374		12,189		12,058
Cryosurgical systems		—		7,054		10,767
Genomics		37,141		56,200		79,754
Microbiome		6,156		7,172		6,690
COVID-19		49,802		—		—
Laboratory services		9,564		6,767		—
Other product revenue		117		675		—
Net product and service revenues		166,381		148,073		165,428
Royalty income		3,432		5,116		9,653
Other non-product revenues		1,908		1,416		6,662
Other revenues		5,340		6,532		16,315
Net revenues	$	171,721	$	154,605	$	181,743

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:

	Years Ended December 31,
	2020		2019		2018
United States	$	130,835	$	107,279	$	136,847
Europe		12,068		11,752		11,062
Other regions		28,818		35,574		33,834
	$	171,721	$	154,605	$	181,743

Computations of Basic and Diluted Earnings Per Share

The computations of basic and diluted earnings (loss) per share are as follows:

	Year ended December 31,
	2020			2019		2018
Net income (loss)	$	(14,922	)	$	16,656	$	20,396
Weighted average shares of common stock outstanding:
Basic		67,505			61,675		61,112
Dilutive effect of stock options, restricted stock, and performance stock units		—			495		1,420
Diluted		67,505			62,170		62,532
Earnings (loss) per share:
Basic	$	(0.22	)	$	0.27	$	0.33
Diluted	$	(0.22	)	$	0.27	$	0.33

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2020

Weighted-Average Assumptions for Fair Value Measurement

The fair value of each stock option was estimated on the date of the grant using the Black-Scholes option-pricing model using the following weighted-average assumptions:

	Years Ended December 31,
Black-Scholes Option Valuation Assumptions	2020			2019			2018
Risk-free interest rate⁽¹⁾		1.33	%		2.52	%		2.60	%
Expected dividend yield		—			—			—
Expected stock price volatility⁽²⁾		42	%		41	%		43	%
Expected life of stock options (in years)⁽²⁾		5			5			6

⁽¹⁾	Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of our stock options.

⁽²⁾	Based upon historical experience.

Schedule of Compensation Expense Recognized in Financial Statements Related to Stock Options

Compensation expense recognized in the financial statements related to stock options was as follows:

	Years Ended December 31,
	2020			2019			2018
Total compensation cost during the year	$	892		$	1,161		$	2,163
Amounts capitalized into inventory during the year		(466	)		(343	)		(420	)
Amounts recognized in cost of products sold for amounts previously capitalized		360			405			396
Amounts charged against income	$	786		$	1,223		$	2,139

Summary of Company's Stock Option Activity

The following table summarizes the stock option activity under the Stock Plan:

	Options			Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding on January 1, 2020		1,193			10.68
Granted		510			7.16
Exercised		(402	)		8.03
Expired		(5	)		8.73
Forfeited		(64	)		10.12
Outstanding on December 31, 2020		1,232		$	10.12		6.79	$	2,688
Vested or expected to vest as of December 31, 2020		1,232		$	10.12		6.79	$	2,688
Exercisable on December 31, 2020		636		$	11.62		4.87	$	1,034

Schedule of Currently Outstanding and Exercisable Stock Options

The following table summarizes information about stock options outstanding as of December 31, 2020:

Options outstanding							Options exercisable
Range of exercise prices	Number Outstanding		Weighted- Average Remaining Contractual Term (in years)		Weighted- Average Exercise Price Per Share		Number Exercisable		Weighted- Average Exercise Price Per Share
$5.37 - $8.24		665		7.7	$	6.94		182	$	6.30
$8.87 - $13.31		368		5.8		10.99		276		10.39
$14.95 - $22.43		199		5.5		19.19		178		18.97
		1,232		6.8	$	10.12		636	$	11.62

Summary of Restricted Stock Award and Restricted Stock Units Activity Under Stock Plan

The following table summarizes restricted stock award and restricted stock units activity under the Stock Plan:

	Units			Weighted-Average Grant Date Fair Value
Issued and unvested, January 1, 2020		464			12.86
Granted		561			8.35
Vested		(342	)		11.14
Forfeited		(24	)		11.90
Issued and unvested, December 31, 2020		659		$	9.95
Issued and expected to vest, December 31, 2020		659		$	9.95

Performance Based Restricted Stock Unit [Member]

Summary of Performance Based Restricted Stock Unit Award Activity Under Stock Plan

The following table summarizes PSU activity under the Stock Plan:

	Units			Weighted- Average Grant Date Fair Value
Issued and unvested, January 1, 2020		525			12.52
Granted⁽¹⁾		368			7.57
Performance adjustment⁽²⁾		104		N/A
Vested		(311	)		8.87
Forfeited		(35	)		13.87
Issued and unvested, December 31, 2020		651		$	11.30
Issued and expected to vest, December 31, 2020		651		$	11.30

^1.

Grant activity for all PSUs disclosed at target.

^2.

Reflects the performance adjustment based on actual performance measured at the end of the performance period.

Leases

12 Months Ended

Dec. 31, 2020

Lessee Disclosure [Abstract]

Leases

9. LEASES:

In February 2016, the FASB issued ASU No. 2016-02, Leases. The standard requires lessees to recognize lease assets and lease liabilities on the balance sheet and requires expanded disclosures about leasing arrangements. We adopted this standard on January 1, 2019 on a modified retrospective basis and did not restate comparative amounts.

We determine whether an arrangement is a lease at inception. We have operating and finance leases for corporate offices, warehouse space and equipment (including vehicles). As of December 31, 2020, we are the lessee in all agreements. Our leases have remaining lease terms of 1 to 7 years, some of which include options to extend the leases based on agreed upon terms, and some of which include options to terminate the leases within 1 year.

As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.

We have lease agreements that contain both lease and non-lease components (e.g., common-area maintenance). For these agreements, we account for lease components separate from non-lease components.

The components of lease expense are as follows:

	Year ended		Year ended
	December 31, 2020		December 31, 2019
Operating Lease Cost	$	1,291	$	964
Finance Lease Cost
Amortization of right-of use assets		627		410
Interest on lease liabilities		72		36
Total Finance Lease Cost	$	699	$	446

Lease cost for the year ended December 31, 2018 was $1,461.

Supplemental cash flow information related to leases is as follows:

	Year ended		Year ended
	December 31, 2020		December 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	1,280	$	937
Operating cash flows from financing leases		72		33
Financing cash flows from financing leases		687		442
Non-cash activity
Right-of-use assets obtained in exchange for operating lease obligations		498		1,829
Right-of-use assets obtained in exchange for finance lease obligations		46		2,069

Right of use assets obtained include those assets acquired and entered into during 2020 and 2019.

Supplemental balance sheet information related to leases is as follows:

	December 31, 2020		December 31, 2019
Operating Leases
Right-of-use assets	$	4,461	$	4,996
Current lease liabilities		1,125		1,032
Non-current lease liabilities		3,591		4,206
Total operating lease liabilities	$	4,716	$	5,238

Finance Leases
Right-of-use assets	$	1,312	$	1,951
Current lease liabilities		517		613
Non-current lease liabilities		895		1,372
Total finance lease liabilities	$	1,412	$	1,985

Weighted Average Remaining Lease Term
Weighted-average remaining lease term—operating leases	4.45
Weighted-average remaining lease term—finance leases	2.67

Weighted Average Discount Rate
Weighted-average discount rate—operating leases	4.28	%
Weighted-average discount rate—finance leases	4.35	%

As of December 31, 2020, minimum lease payments by period are expected to be as follows:

	Finance			Operating
2021		566			1,332
2022		566			1,315
2023		337			874
2024		25			894
2025		4			520
Thereafter		-			325
Total Minimum Lease Payments		1,498			5,260
Less: imputed interest		(86	)		(544	)
Present Value of Lease Liabilities	$	1,412		$	4,716

Business Combinations (Tables)

12 Months Ended

Dec. 31, 2020

Summary of Unaudited Pro Forma Financial Information

The unaudited pro forma results presented below include the results of the CoreBiome, Diversigen, Novosanis acquisitions as if they had been consummated as of January 1, 2018 and the results of UrSure as if it had been consummated as of January 31, 2019. The unaudited pro forma results include the amortization associated with acquired intangible assets and the estimated tax effect of adjustments to income before income taxes but do not include changes in the fair value of our contingent consideration obligations. Material nonrecurring charges, directly attributable to the transactions, including direct acquisition costs, are also excluded. In addition, the unaudited pro forma results do not include any expected benefits of the acquisitions. Accordingly, the unaudited pro forma results are not necessarily indicative of either future results of operations or results that might have been achieved had the acquisitions been consummated as of the January 1, 2018 and 2019 dates.

	Year Ended December 31,
	2020			2019		2018

Revenue	$	172,563		$	159,632	$	190,487
Net income		(14,937	)		16,261		19,448
Net income per share, basic		(0.22	)		0.26		0.32
Net income per share, diluted		(0.22	)		0.26		0.31

UrSure Inc [Member]

Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:

Assets Acquired
Accounts receivable	$	285
Other current assets		24
Other assets		6
Intangibles		3,600
Goodwill		3,586
Total assets acquired		7,501
Liabilities Assumed
Current liabilities		335
Deferred tax liability		689
Total liabilities assumed		1,024
Net Assets Acquired		6,477
Estimated fair value of contingent consideration		(3,440	)
Net Cash Paid (net of cash acquired of $111)	$	3,037

Diversigen, Inc. [Member]

Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed

The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:

Assets Acquired
Accounts receivable	$	1,234
Other current assets		45
Property, plant, and equipment, net		1,916
Acquired intangible assets		3,560
Goodwill		6,317
Total assets acquired		13,072
Liabilities Assumed
Current liabilities		1,123
Deferred tax liability		598
Other long-term liabilities		893
Total liabilities assumed		2,614
Net Assets Acquired		10,458
Estimated fair value of contingent consideration		-
Net Cash Paid (net of cash acquired of $479)	$	10,458

Summary of Identifiable Intangible Assets Subject to Amortization on Straight-line Basis and Being Amortized over Estimated Useful Lives

The identifiable intangible assets included customer relationships and tradenames, all of which are subject to amortization on a straight-line basis and are being amortized over estimated useful lives as summarized below:

	Estimated Useful
Description	Life (in yrs)	Amount
Customer relationships	10		2,900
Tradenames	9		660
Total acquired intangibles		$	3,560

Corebiome Inc. and Novosanis NV [Member]

Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:


Assets Acquired
Accounts receivable	$	791
Inventories		310
Other current assets		82
Property, plant, and equipment, net		414
Other assets		5
Acquired intangible assets		8,400
Goodwill		10,368
Total assets acquired		20,370
Liabilities Assumed
Current liabilities		1,180
Notes payable, short-term		730
Deferred tax liability		819
Other long-term liabilities		74
Total liabilities assumed		2,803
Net Assets Acquired		17,567
Estimated fair value of contingent consideration		(4,350	)
Net Cash Paid (net of cash acquired of $103)	$	13,217

Summary of Identifiable Intangible Assets Subject to Amortization on Straight-line Basis and Being Amortized over Estimated Useful Lives

The identifiable intangible assets principally included developed technology, customer relationships, and tradenames, all of which are subject to amortization on a straight-line basis and are being amortized over estimated useful lives as summarized below:

	Estimated Useful
Description	Life (in yrs)	Amount
Developed Technology	10	$	5,000
Customer relationships	10		2,200
Tradenames	8.34		1,200
Total acquired intangibles		$	8,400

Accrued Expenses

12 Months Ended

Dec. 31, 2020

Payables And Accruals [Abstract]

Accrued Expenses

8.	ACCRUED EXPENSES:

	December 31,
	2020		2019
Payroll and related benefits	$	14,769	$	6,088
Professional fees		978		2,769
Other		6,480		5,431
	$	22,227	$	14,288

Commitments and Contingencies

12 Months Ended

Dec. 31, 2020

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

14.	COMMITMENTS AND CONTINGENCIES:

Purchase Commitments

As of December 31, 2020, we had outstanding non-cancelable purchase commitments related to inventory, supplies, capital expenditures, and other goods or services as follows:

2021		16,542
2022		20
2023		18
	$	16,580

Employment Agreements

Under terms of employment agreements with certain employees, which extend through 2024, we are required to pay each individual a base salary for continuing employment with us as follows:

2021		2,947
2022		1,213
2023		409
2024		—
	$	4,569

Litigation

From time to time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, the outcomes of such actions, either individually or in the aggregate, are not expected to have a material adverse effect on our future financial position or results of operations.

On February 6, 2017, DNAG entered into a settlement and license agreement (the “Settlement Agreement”) in order to settle certain patent infringement and breach of contract litigation against Ancestry.comDNA, LLC (“Ancestry”) and its contract manufacturer. This litigation was related to a saliva DNA collection device sold by Ancestry that was similar to products sold by DNAG. Under the terms of the Settlement Agreement, DNAG and Ancestry agreed to certain procedures for considering whether future versions of Ancestry’s saliva DNA collection product are covered by the DNAG patents licensed to Ancestry (the “Licensed Patents”) and thus subject to ongoing royalties under the Settlement Agreement. A dispute arose among the parties regarding whether certain new Ancestry products are covered by the Licensed Patents. Pursuant to the terms of the Settlement Agreement, a binding arbitration proceeding was commenced to resolve the dispute. In February 2020, an arbitration panel issued a decision finding that the future Ancestry products do not infringe the DNAG patents asserted in the arbitration and would no longer be subject to the royalties under the Settlement Agreement.

Following the completion of the arbitration, a new patent was issued to DNAG that is a continuation of a patent licensed to Ancestry and is thus a Licensed Patent under the Settlement Agreement. DNAG notified Ancestry of this new patent and following discussions between the parties Ancestry initiated a new arbitration proceeding during the third quarter of 2020 pursuant to the Settlement Agreement with respect to the applicability of the new patent to the future Ancestry products and the validity of that patent. Following the initiation of the arbitration by Ancestry, DNAG filed a statement of defense and an objection to the arbitration on the basis that a dispute between the parties has not yet occurred and therefore the alleged dispute is not sufficiently ripe to arbitrate. An arbitration panel has been appointed. The parties have since engaged in settlement discussions and the commencement of the arbitration has been delayed.

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
NET REVENUES:
Total revenue	$ 171,721	$ 154,605	$ 181,743
COST OF PRODUCTS SOLD	69,853	60,022	68,130
Gross profit	101,868	94,583	113,613
OPERATING EXPENSES:
Research and development	31,032	19,629	16,250
Sales and marketing	34,459	31,869	30,609
General and administrative	42,653	35,287	38,325
Change in the estimated fair value of acquisition-related contingent consideration	(1,099)	(664)
Gain on sale of business		(10,149)
Total operating expenses	107,045	75,972	85,184
Operating income (loss)	(5,177)	18,611	28,429
OTHER INCOME	1,653	2,720	3,287
Income (loss) before income taxes	(3,524)	21,331	31,716
INCOME TAX EXPENSE	11,398	4,675	11,320
NET INCOME (LOSS)	$ (14,922)	$ 16,656	$ 20,396
EARNINGS (LOSS) PER SHARE:
BASIC	$ (0.22)	$ 0.27	$ 0.33
DILUTED	$ (0.22)	$ 0.27	$ 0.33
SHARES USED IN COMPUTING EARNINGS (LOSS) PER SHARE:
BASIC	67,505	61,675	61,112
DILUTED	67,505	62,170	62,532
Products and Services [Member]
NET REVENUES:
Total revenue	$ 166,381	$ 148,073	$ 165,428
Other Revenues [Member]
NET REVENUES:
Total revenue	$ 5,340	$ 6,532	$ 16,315

Leases - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2018
Lessee Lease Description [Line Items]
Lessee operating and financing lease existence of option to terminate	true
Lessee operating and financing leases, period of options to terminate	1 year
Lessee, operating and finance lease, existence of option to extend	true
Lease cost		$ 1,461
Minimum [Member]
Lessee Lease Description [Line Items]
Operating and financing leases, remaining lease terms	1 year
Maximum [Member]
Lessee Lease Description [Line Items]
Operating and financing leases, remaining lease terms	7 years

Stockholders' Equity - Schedule of Currently Outstanding and Exercisable Stock Options (Detail) shares in Thousands	12 Months Ended
	Dec. 31, 2020 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding, Options outstanding \| shares	1,232
Weighted-Average Remaining Contractual Term (in years), Options outstanding	6 years 9 months 18 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 10.12
Number Exercisable, Options exercisable \| shares	636
Weighted-Average Exercise Price Per Share, Options exercisable	$ 11.62
Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	5.37
Range of exercise prices, Upper Range Limit	$ 8.24
Number Outstanding, Options outstanding \| shares	665
Weighted-Average Remaining Contractual Term (in years), Options outstanding	7 years 8 months 12 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 6.94
Number Exercisable, Options exercisable \| shares	182
Weighted-Average Exercise Price Per Share, Options exercisable	$ 6.30
Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	8.87
Range of exercise prices, Upper Range Limit	$ 13.31
Number Outstanding, Options outstanding \| shares	368
Weighted-Average Remaining Contractual Term (in years), Options outstanding	5 years 9 months 18 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 10.99
Number Exercisable, Options exercisable \| shares	276
Weighted-Average Exercise Price Per Share, Options exercisable	$ 10.39
Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	14.95
Range of exercise prices, Upper Range Limit	$ 22.43
Number Outstanding, Options outstanding \| shares	199
Weighted-Average Remaining Contractual Term (in years), Options outstanding	5 years 6 months
Weighted-Average Exercise Price Per Share, Options outstanding	$ 19.19
Number Exercisable, Options exercisable \| shares	178
Weighted-Average Exercise Price Per Share, Options exercisable	$ 18.97

Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward
Balance as of January 1	$ 1,308	$ 1,676	$ 1,663
Additions for tax positions of prior periods	1	4	44
Reductions for tax positions of prior periods	(137)	(372)	(31)
Balance as of December 31	$ 1,172	$ 1,308	$ 1,676

Stockholders' Equity

12 Months Ended

Dec. 31, 2020

Equity [Abstract]

Stockholders' Equity

11.	STOCKHOLDERS’ EQUITY:

Stock-Based Awards

We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards.

As of December 31, 2020, 5,595 shares were available for future grants under the Stock Plan.

Under the terms of the Stock Plan, nonqualified stock options may be granted to eligible employees, including our officers at a price not less than 75 percent of the fair market value of a share of common stock on the date of grant. The option term and vesting schedule of such awards may be either unlimited or have a specified period in which to vest and be exercised. To date, options generally have been granted with ten-year exercise periods and an exercise price not less than the fair market value on the date of grant. Options generally vest over four years, with one quarter of the options vesting one year after grant and the remainder vesting on a monthly basis over the next three years.

The fair value of each stock option was estimated on the date of the grant using the Black-Scholes option-pricing model using the following weighted-average assumptions:

	Years Ended December 31,
Black-Scholes Option Valuation Assumptions	2020			2019			2018
Risk-free interest rate⁽¹⁾		1.33	%		2.52	%		2.60	%
Expected dividend yield		—			—			—
Expected stock price volatility⁽²⁾		42	%		41	%		43	%
Expected life of stock options (in years)⁽²⁾		5			5			6

⁽¹⁾	Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of our stock options.

⁽²⁾	Based upon historical experience.

The weighted-average grant date fair value of stock options granted during the years ended December 31, 2020, 2019 and 2018 was $2.79, $5.19 and $9.15, respectively.

Compensation expense recognized in the financial statements related to stock options was as follows:

	Years Ended December 31,
	2020			2019			2018
Total compensation cost during the year	$	892		$	1,161		$	2,163
Amounts capitalized into inventory during the year		(466	)		(343	)		(420	)
Amounts recognized in cost of products sold for amounts previously capitalized		360			405			396
Amounts charged against income	$	786		$	1,223		$	2,139

The aggregate intrinsic value of options exercised during the years ended December 31, 2020, 2019, and 2018 (the amount by which the market price of the stock on the date of exercise exceeded the exercise price) was $3,117, $92, and $2,314, respectively.

The following table summarizes the stock option activity under the Stock Plan:

	Options			Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding on January 1, 2020		1,193			10.68
Granted		510			7.16
Exercised		(402	)		8.03
Expired		(5	)		8.73
Forfeited		(64	)		10.12
Outstanding on December 31, 2020		1,232		$	10.12		6.79	$	2,688
Vested or expected to vest as of December 31, 2020		1,232		$	10.12		6.79	$	2,688
Exercisable on December 31, 2020		636		$	11.62		4.87	$	1,034

As of December 31, 2020, there was $1,689 of unrecognized compensation expense related to unvested option awards that is expected to be recognized over a weighted-average period of 2.6 years.

Net cash proceeds from the exercise of stock options were $3,222, $196 and $1701 for the years ended December 31, 2020, 2019, and 2018, respectively. As a result of our net operating loss carryforward position, no actual income tax benefit was realized from stock option exercises for these periods.

The following table summarizes information about stock options outstanding as of December 31, 2020:

Options outstanding							Options exercisable
Range of exercise prices	Number Outstanding		Weighted- Average Remaining Contractual Term (in years)		Weighted- Average Exercise Price Per Share		Number Exercisable		Weighted- Average Exercise Price Per Share
$5.37 - $8.24		665		7.7	$	6.94		182	$	6.30
$8.87 - $13.31		368		5.8		10.99		276		10.39
$14.95 - $22.43		199		5.5		19.19		178		18.97
		1,232		6.8	$	10.12		636	$	11.62

The Stock Plan also permits us to grant restricted shares and restricted units of our common stock to eligible employees, including officers, and our outside directors. Generally, these shares or units are nontransferable until vested and are subject to vesting requirements and/or forfeiture, as determined by our Compensation Committee or Board of Directors. The market value of these shares and units at the date of grant is recognized on a straight-line basis over the period during which the restrictions lapse. Compensation cost of $4,094 $2,979 and $6,357 related to restricted shares was recognized during the years ended December 31, 2020, 2019, and 2018, respectively.

The following table summarizes restricted stock award and restricted stock units activity under the Stock Plan:

	Units			Weighted-Average Grant Date Fair Value
Issued and unvested, January 1, 2020		464			12.86
Granted		561			8.35
Vested		(342	)		11.14
Forfeited		(24	)		11.90
Issued and unvested, December 31, 2020		659		$	9.95
Issued and expected to vest, December 31, 2020		659		$	9.95

As of December 31, 2020, there was $3,697 of unrecognized compensation expense related to unvested restricted stock awards and unvested restricted stock units that is expected to be recognized over a weighted average period of 1.7 years.

In connection with the vesting of restricted shares during the years ended December 31, 2020, 2019 and 2018, we purchased and immediately retired 127, 76 and 171 shares with aggregate values of $1,219, $949 and $3,291, respectively, in satisfaction of minimum tax withholding and exercise obligations.

We grant performance-based restricted stock units (“PSUs”) to certain executives. Vesting of these PSUs is dependent upon achievement of performance-based metrics during a one-year or three-year period, from the date of grant. Assuming achievement of each performance-based metric, the executive must also generally remain in our service for three years from the grant date. Performance during the one-year period will be based on a one-year earnings per share or income before taxes target. If the one-year target is achieved, the PSUs will then vest three years from grant date. Performance during the three-year period will be based on achievement of a three-year compound annual growth rate for consolidated product revenues. If the three-year target is achieved, the corresponding PSUs will then vest three years from grant date. PSUs are converted into shares of our common stock once vested. Upon grant of the PSUs, we recognize compensation expense related to these awards based on assumptions as to what percentage of each target will be achieved. The Company evaluates these target assumptions on a quarterly basis and adjusts compensation expense related to these awards, as appropriate.

Compensation cost of $2,153, $(83) and $6,717 related to the PSUs was recognized during the years ended December 31, 2020, 2019 and 2018, respectively.

The following table summarizes PSU activity under the Stock Plan:

	Units			Weighted- Average Grant Date Fair Value
Issued and unvested, January 1, 2020		525			12.52
Granted⁽¹⁾		368			7.57
Performance adjustment⁽²⁾		104		N/A
Vested		(311	)		8.87
Forfeited		(35	)		13.87
Issued and unvested, December 31, 2020		651		$	11.30
Issued and expected to vest, December 31, 2020		651		$	11.30

^1.

Grant activity for all PSUs disclosed at target.

^2.

Reflects the performance adjustment based on actual performance measured at the end of the performance period.

In connection with the vesting of performance stock units during the year ended December 31, 2020, 2019 and 2018, we purchased and immediately retired 121, 213, and 20 shares with aggregate values of $869, $2,763 and $301, respectively.

Public Offering

On June 1, 2020, we entered into an underwriting agreement with J.P. Morgan Securities LLC, Citigroup Global Markets Inc. and Evercore Group LLC, as representatives of several underwriters, relating to the issuance and sale of 8,000 shares of our common stock. The price to the public in the offering was $11.00 per share. Under the terms of the underwriting agreement, we also granted the underwriters an option, exercisable for 30 days, to purchase up to an additional 1,200 shares of common stock. On June 3, 2020, we announced the full exercise by the underwriters of their option to purchase these additional shares.

The offering was made pursuant to an effective registration statement on Form S-3 (File No. 333-228877) we had previously filed with the SEC, and a prospectus supplement thereunder. The net proceeds from the offering were approximately $95,000 after deducting underwriting discounts and offering expenses paid by the Company.

Share Repurchase Program

On August 5, 2008, our Board of Directors approved a share repurchase program pursuant to which we are permitted to acquire up to $25,000 of our outstanding common shares. No shares were purchased and retired in 2020, 2019 or 2018.

Leases - Summary of Supplemental Cash Flow Information Related to Leases (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 1,280	$ 937
Operating cash flows from financing leases	72	33
Financing cash flows from financing leases	687	442
Non-cash activity
Right-of-use assets obtained in exchange for operating lease obligations	498	1,829
Right-of-use assets obtained in exchange for finance lease obligations	$ 46	$ 2,069

Property, Plant and Equipment (Tables)

12 Months Ended

Dec. 31, 2020

Property Plant And Equipment [Abstract]

Schedule of Property, Plant and Equipment

	December 31,
	2020			2019
Land	$	1,118		$	1,118
Buildings and improvements		26,480			23,231
Machinery and equipment		36,878			33,568
Computer equipment and software		13,024			11,590
Furniture and fixtures		3,545			2,791
Construction in progress		24,419			4,923
		105,464			77,221
Less accumulated depreciation		(53,604	)		(46,882	)
	$	51,860		$	30,339

The Company

12 Months Ended

Dec. 31, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

The Company

1.	THE COMPANY:

The overall goal of OraSure Technologies, Inc. (“OraSure” or “the Company”) is to empower the global community to improve health and wellness by providing access to accurate essential information. Our business consists of two segments: our “Diagnostics” segment, which was previously named “OSUR” and our “Molecular Solutions” segment, which was previously name “DNAG”. Our Diagnostics business primarily consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using our proprietary technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our Molecular Solutions business consists of the manufacture and sale of kits that are used to collect, stabilize, transport and store biological samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, infectious disease diagnostics, pharmacogenomics, personalized medicine, microbiome and animal genetics markets. Our collection kits are also used for the collection of first-void urine for liquid biopsy in the prostate and bladder cancer markets and in the sexually transmitted infection screening market. In addition, our Molecular Solutions business provides microbiome laboratory and bioinformatics services.

The Diagnostics business includes tests for diseases including HIV and Hepatitis C that are performed on a rapid basis at the point of care and tests that are processed in a laboratory. These products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Our HIV product is also sold in a consumer-friendly format in the over-the-counter (“OTC”) market in the U.S. and as a self-test to individuals in a number of other countries. Our Diagnostics business includes the operations of UrSure, Inc. (“UrSure”), which was acquired and merged into OraSure in 2020. This part of the business develops and commercializes products that measure adherence to HIV medications including pre-exposure prophylaxis or PrEP, the daily medication to prevent HIV. These products include laboratory-based tests that can measure levels of the medication in a patient’s urine or blood, as well as point of care products currently in development. We also previously manufactured and sold medical devices used for the removal of benign skin lesions by cryosurgery or freezing. We sold the assets associated with our cryosurgical systems business to a third party in August 2019. In 2020, we began the development of a rapid antigen self-test for COVID-19 and a COVID-19 antibody ELISA test for use in laboratory settings. We expect to begin selling these products in 2022.

Our Molecular Solutions business is operated by our subsidiaries, DNA Genotek Inc. (“DNAG”), Diversigen, Inc. (“Diversigen”), and Novosanis NV (“Novosanis”). In DNAG’s business, we manufacture and sell kits that are used to collect, stabilize, transport and store biological sample of genetic material for molecular testing. Our products are used for academic research and commercial applications, including ancestry, disease risk management, lifestyle and animal testing. In 2020, two of our collection devices were used in connection with COVID-19 molecular testing. We also sell research use only collection products into the microbiome market. We offer our customers a suite of genomics and microbiome services that range from package customization and study design optimization to extraction, analysis and reporting services. The microbiome laboratory and bioinformatics services are provided by Diversigen, which includes the operations of CoreBiome, Inc. (“CoreBiome”), a subsidiary we acquired in early 2019. CoreBiome and Diversigen were merged together in 2020. Novosanis manufactures and sells the Colli-Pee® collection device for the volumetric collection of first-void urine for use in research, screening and diagnostics in the liquid biopsy and sexually transmitted infection markets. Our Molecular Solutions business serves customers in many countries worldwide, including many leading research universities and hospitals.

Business Combinations

12 Months Ended

Dec. 31, 2020

Business Combinations [Abstract]

Business Combinations

3. BUSINESS COMBINATIONS

UrSure

On July 22, 2020, the Company acquired all of the outstanding stock of UrSure, Inc. (“UrSure”), pursuant to the terms of a merger agreement. The initial aggregate purchase price of this transaction was $3,000, adjusted for certain transaction costs, indebtedness, and holdback amounts, and was funded with cash on hand. A portion of the purchase price was deposited into an escrow account for a limited period after closing, pursuant to indemnification obligations under the merger agreement.

Pursuant to our acquisition agreements, we may pay up to an additional $28,000 of contingent consideration over the next four years based on the achievement of certain performance criteria as defined under the agreements, including generating certain revenue

dollars, and the achievement of certain clinical milestones associated with the development of certain new technology. The Company, with the assistance of an independent valuation specialist, determined the estimated acquisition-date fair value of the acquisition-related contingent consideration of $3,440. The fair value was determined using a probability-weighted model based on our assessment of the likelihood that the benchmarks will be achieved. The probability-weighted payments were then discounted using a discount rate based on an internal rate of return analysis using the probability-weighted cash flows. The fair value measurement was based on significant inputs, including the likelihood of the achievement of clinical milestones and revenue forecasts, not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the contingent consideration obligation changed from $3,440 as of the acquisition date to $2,451 as of December 31, 2020 largely due to changes in the timing of achieving certain clinical milestones.

During the year ended December 31, 2020, we incurred a total of $393 of acquisition related costs, including accounting, legal, and other professional fees, all of which were expensed and reported as a component of general and administrative expense in the consolidated statement of operations for the year ended December 31, 2020.The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:

Assets Acquired
Accounts receivable	$	285
Other current assets		24
Other assets		6
Intangibles		3,600
Goodwill		3,586
Total assets acquired		7,501
Liabilities Assumed
Current liabilities		335
Deferred tax liability		689
Total liabilities assumed		1,024
Net Assets Acquired		6,477
Estimated fair value of contingent consideration		(3,440	)
Net Cash Paid (net of cash acquired of $111)	$	3,037

The purchase price was allocated to the tangible assets and identifiable intangible assets acquired and liabilities assumed based on their acquisition-date estimate fair values. The identifiable intangible assets principally included developed technology, which is subject to amortization on a straight-line basis and is being amortized over a ten year estimated useful life.

The Company, with the assistance of an independent valuation specialist, assessed the fair value of the assets of UrSure. The income approach was used to value the acquired intangibles and the fair value measurements were primarily based on significant inputs that are not observable in the market and are considered Level 3 fair value measurements. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money.

The useful lives of the intangible assets were estimated based on the expected future economic benefit of the assets and are being amortized over the estimated useful life in proportion to the economic benefits consumed using the straight-line method.

The amortization of intangible assets is not deductible for income tax purposes.

Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the fair value of the net assets acquired, and represents the future economic benefits that we expect to achieve as a result of the acquisition. We believe the goodwill related to the acquisition was a result of gaining a complementary product offering that will enable us to leverage those products with existing and new customers. The goodwill is not deductible for income tax purposes. All of the goodwill identified above has been allocated to our Diagnostics segment.

We continue to evaluate the fair value of certain assets acquired and liabilities assumed, related to the acquisition. Additional information that existed as of the acquisition date, but was at that time unknown to us, may become known during the remainder of the measurement period. Changes to amounts recorded as a result of the final determination may result in a corresponding adjustment to these assets and liabilities, including goodwill. The determination of the estimated fair values of all assets acquired is expected to be completed within one year from the date of acquisition.

Revenues from UrSure primarily consist of grant money received to fund the development of certain new technology and approximated $842 since acquisition. Effective as of July 22, 2020, the financial results of UrSure are included in our Diagnostics segment.

Diversigen

On November 8, 2019, the Company acquired all of the outstanding stock of Diversigen pursuant to the terms of a merger agreement. The aggregate purchase price for this transaction was $12,000, adjusted for certain transaction costs, indebtedness, and holdback amounts, and was funded with cash on hand. A portion of the purchase price was deposited into an escrow account for a limited period after closing, pursuant to indemnification obligations under the merger agreement noted above.

During the year ended December 31, 2019, we incurred a total of $1,198 of acquisition related costs, including investment banking fees and accounting, legal and other professional fees, all of which were expensed and reported as a component of general and administrative expenses in the consolidated statement of operations for the year ended December 31, 2019.

Pursuant to the merger agreement, we were to pay up to an additional $1,500 of contingent consideration in 2020 based on the achievement of certain 2019 revenue metrics as defined under the agreements which did not occur.

The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:

Assets Acquired
Accounts receivable	$	1,234
Other current assets		45
Property, plant, and equipment, net		1,916
Acquired intangible assets		3,560
Goodwill		6,317
Total assets acquired		13,072
Liabilities Assumed
Current liabilities		1,123
Deferred tax liability		598
Other long-term liabilities		893
Total liabilities assumed		2,614
Net Assets Acquired		10,458
Estimated fair value of contingent consideration		-
Net Cash Paid (net of cash acquired of $479)	$	10,458

The purchase price was allocated to the tangible assets and identifiable intangible assets acquired and liabilities assumed based on their acquisition-date estimate fair values. The identifiable intangible assets included customer relationships and tradenames, all of which are subject to amortization on a straight-line basis and are being amortized over estimated useful lives as summarized below:

	Estimated Useful
Description	Life (in yrs)	Amount
Customer relationships	10		2,900
Tradenames	9		660
Total acquired intangibles		$	3,560

The Company, with the assistance of an independent valuation specialist, assessed the fair value of the assets of Diversigen. The income approach was used to value the acquired intangibles and the fair value measurements were primarily based on significant inputs that are not observable in the market and are considered Level 3 fair value measurements. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money.

The amortization of intangible assets is not deductible for income tax purposes.

Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the fair value of the net assets acquired, and represents the future economic benefits that we expect to achieve as a result of the acquisition. We believe the goodwill related to the acquisitions was a result of providing us a complementary service and product offering that will enable us to leverage those services and products with existing and new customers. The goodwill is not deductible for income tax purposes. All of the goodwill identified above has been allocated to our Molecular Solutions segment.

Revenues from Diversigen primarily consist of microbiome laboratory services that provide metagenomics sequencing, bioinformatics and statistical analysis for the study of the microbiome. Effective as of November 8, 2019, the financial results of Diversigen are included in our Molecular Solutions segment. For the year ended December 31, 2019, consolidated net revenues include revenues associated with the Diversigen business of $1,046 and consolidated results from operations include a net loss of $47 generated since the acquisition date.

CoreBiome and Novosanis

On January 4, 2019, the Company acquired all of the outstanding stock of CoreBiome, pursuant to the terms of a merger agreement, dated January 3, 2019. CoreBiome has subsequently been merged into Diversigen in December 2020. Also on January 4, 2019, the Company, through a wholly-owned subsidiary, acquired all of the outstanding stock of Novosanis, pursuant to a share purchase agreement, dated January 3, 2019. We began operating these entities as of the January 4, 2019 closing date. The aggregate purchase price for both of these transactions was $13,320 adjusted for certain transaction costs, indebtedness, and holdback amounts, and was funded with cash on hand. A portion of the purchase price was deposited into escrow accounts for a limited period after closing, in order to secure the potential payment of certain indemnification obligations of the selling stockholders under each agreement noted above.

During the year ended December 31, 2019, we incurred a total of $639 of acquisition-related costs in connection with these acquisitions, including success-based investment banking fees and accounting, legal and other professional fees, related to both acquisitions, all of which were expensed and reported as a component of general and administrative expenses in the consolidated statement of operation.

Pursuant to our acquisition agreements, we were to pay up to an additional $32,400 of contingent consideration over three years based on the achievement of certain performance criteria as defined under the agreements, including generating certain revenue dollars, the achievement of a large customer contract, and the development of certain new technology. The Company, with the assistance of an independent valuation specialist, utilized a Monte Carlo simulation to determine the estimated acquisition-date fair value of the acquisition-related contingent consideration of $4,350. The simulation calculated the probability-weighted payments based on our assessment of the likelihood that the benchmarks will be achieved. The probability-weighted payments were then discounted using a discount rate based on an internal rate of return analysis using the probability-weighted cash flows. The fair value measurement was based on significant inputs, including revenue forecasts, not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the contingent consideration obligation changed from $4,350 as of the acquisition date to $3,612 as of December 31, 2019. This change was a result of changes in our estimated revenue forecasts and an amendment to one of the agreements, entered into in October 2019, in which management agreed to settle the contingent consideration associated with one of the acquisition’s 2019 results for $3,500. The fair value of the contingent consideration obligation changed from $3,612 as of December 31, 2019 to $0 as of December 31, 2020. This change is a result of a $3,500 payment made in the first quarter of 2020, changes in our estimated revenue forecasts and an amendment to one of the agreements. As of December 31, 2020, and based on current and forecasted revenue results, it is not expected than any further contingent consideration will be paid through the final potential payment date of July 2021.

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:


Assets Acquired
Accounts receivable	$	791
Inventories		310
Other current assets		82
Property, plant, and equipment, net		414
Other assets		5
Acquired intangible assets		8,400
Goodwill		10,368
Total assets acquired		20,370
Liabilities Assumed
Current liabilities		1,180
Notes payable, short-term		730
Deferred tax liability		819
Other long-term liabilities		74
Total liabilities assumed		2,803
Net Assets Acquired		17,567
Estimated fair value of contingent consideration		(4,350	)
Net Cash Paid (net of cash acquired of $103)	$	13,217

The purchase price was allocated to the tangible assets and identifiable intangible assets acquired and liabilities assumed based on their acquisition-date estimate fair values. The identifiable intangible assets principally included developed technology, customer relationships, and tradenames, all of which are subject to amortization on a straight-line basis and are being amortized over estimated useful lives as summarized below:

	Estimated Useful
Description	Life (in yrs)	Amount
Developed Technology	10	$	5,000
Customer relationships	10		2,200
Tradenames	8.34		1,200
Total acquired intangibles		$	8,400

The Company, with the assistance of an independent valuation specialist, assessed the fair value of the assets of CoreBiome and Novosanis. The income approach was used to value the acquired intangibles and the fair value measurements were primarily based on significant inputs that are not observable in the market and are considered Level 3 fair value measurements. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money.

The amortization of intangible assets is not deductible for income tax purposes.

Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the fair value of the net assets acquired, and represents the future economic benefits that we expect to achieve as a result of the acquisition. We believe the goodwill related to the acquisitions was a result of providing us a complementary service and product offering that will enable us to leverage those services and products with existing and new customers. The goodwill is not deductible for income tax purposes. All of the goodwill identified above has been allocated to our Molecular Solutions segment.

Revenues from CoreBiome primarily consist of microbiome laboratory services that utilize optimal analytical algorithms to deliver speed and scalability in the lab with precise analytics. Revenues from Novosanis primarily consist of the sale of its Colli-Pee collection device which was designed for the standard collection of first-void urine used in the liquid biopsy and sexually transmitted infection screening market. Effective as of January 4, 2019, the financial results of CoreBiome and Novosanis are included in our

Molecular Solutions segment. For the year ended December 31, 2019, consolidated net revenues include combined revenues associated with the CoreBiome and Novosanis business of $5,152. Consolidated results from operations for the year ended December 31, 2019 included a net loss of $2,450 generated from the combined companies since the acquisition date.

Unaudited Pro Forma Financial Information

	Year Ended December 31,
	2020			2019		2018

Revenue	$	172,563		$	159,632	$	190,487
Net income		(14,937	)		16,261		19,448
Net income per share, basic		(0.22	)		0.26		0.32
Net income per share, diluted		(0.22	)		0.26		0.31

Leases - Summary of Components of Lease Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Lease Cost [Abstract]
Operating Lease Cost	$ 1,291	$ 964
Finance Lease Cost
Amortization of right-of use assets	627	410
Interest on lease liabilities	72	36
Total Finance Lease Cost	$ 699	$ 446

Business Combinations - Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed (Parenthetical) (Detail) - USD ($) $ in Thousands				12 Months Ended
	Jul. 22, 2020	Nov. 08, 2019	Jan. 04, 2019	Dec. 31, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Net of cash acquired				$ 3,037	$ 23,801
UrSure Inc [Member]
Business Acquisition [Line Items]
Net of cash acquired	$ 111
Diversigen, Inc. [Member]
Business Acquisition [Line Items]
Net of cash acquired		$ 479
Corebiome Inc. and Novosanis NV [Member]
Business Acquisition [Line Items]
Net of cash acquired			$ 103

Goodwill and Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2020

Goodwill And Intangible Assets Disclosure [Abstract]

Schedule of Changes in Goodwill

The changes in goodwill are as follows:

	December 31,
	2020			2019
Balance as of January 1		36,201			18,521
Goodwill acquired during the year		3,586			16,811
Purchase price adjustment		(126	)		—
Change related to foreign currency translation		690			869
Balance as of December 31	$	40,351		$	36,201

Summary of Intangible Assets

Intangible assets consist of the following:

			December 31, 2020
	Amortization Period (Years)		Gross		Accumulated Amortization			Net

Customer relationships		10	$	14,997	$	(9,685	)	$	5,312
Patents and product rights		5		7,766		(5,792	)		1,974
Developed technology	7-10			16,603		(8,880	)		7,723
Tradename	5-15			5,645		(2,750	)		2,895
			$	45,011	$	(27,107	)	$	17,904

			December 31, 2019
	Amortization Period (Years)		Gross		Accumulated Amortization			Net
Customer relationships		10	$	14,731	$	(8,054	)	$	6,677
Patents and product rights		10		5,400		(5,158	)		242
Developed technology	7-10			12,410		(7,982	)		4,428
Tradename	5-15			5,553		(2,226	)		3,327
			$	38,094	$	(23,420	)	$	14,674

Summary of Amortization Expense

Amortization expense for each of the five succeeding fiscal years and beyond is estimated as follows:

2021		3,291
2022		2,345
2023		2,345
2024		2,302
2025		2,050
Beyond		5,571
	$	17,904

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Accrued Liabilities Current [Abstract]
Payroll and related benefits	$ 14,769	$ 6,088
Professional fees	978	2,769
Other	6,480	5,431
Accrued Expenses, Total	$ 22,227	$ 14,288

Inventories (Tables)

12 Months Ended

Dec. 31, 2020

Inventory Disclosure [Abstract]

Schedule of Inventories

	December 31,
	2020		2019
Raw materials	$	15,425	$	14,168
Work in process		2,572		643
Finished goods		13,866		8,344
	$	31,863	$	23,155

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Revision of Prior Period, ASU, Adjustment [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]	Accumulated Deficit [Member] Revision of Prior Period, ASU, Adjustment [Member]
Beginning Balance at Dec. 31, 2017	$ 258,081			$ 387,931	$ (10,340)	$ (119,510)
Beginning Balance (Adoption of ASU 2014-9) at Dec. 31, 2017		$ (75)					$ (75)
Beginning Balance, Shares at Dec. 31, 2017			60,662
Common stock issued upon exercise of options	1,697			1,697
Common stock issued upon exercise of options, Shares			227
Vesting of restricted stock	0		$ 0	0	0	0
Vesting of restricted stock, Shares			578
Purchase and retirement of common shares	(3,592)			(3,592)
Purchase and retirement of common shares, Shares			(191)
Stock-based compensation	15,237			15,237
NET INCOME (LOSS)	20,396					20,396
Currency translation adjustments	(8,003)				(8,003)
Unrealized gain (loss) on marketable securities	(363)				(363)
Ending Balance at Dec. 31, 2018	283,378			401,273	(18,706)	(99,189)
Ending Balance, Shares at Dec. 31, 2018			61,276
Common stock issued upon exercise of options	196			196
Common stock issued upon exercise of options, Shares			27
Vesting of restricted stock and performance stock units, Shares			717
Purchase and retirement of common shares	(3,712)			(3,712)
Purchase and retirement of common shares, Shares			(289)
Stock-based compensation	4,057			4,057
NET INCOME (LOSS)	16,656					16,656
Currency translation adjustments	5,767				5,767
Unrealized gain (loss) on marketable securities	803				803
Ending Balance at Dec. 31, 2019	307,145			401,814	(12,136)	(82,533)
Ending Balance, Shares at Dec. 31, 2019			61,731
Common stock issued upon exercise of options	$ 3,222			3,222
Common stock issued upon exercise of options, Shares	402		402
Vesting of restricted stock and performance stock units	$ 0		$ 0	0	0	0
Vesting of restricted stock and performance stock units, Shares			653
Purchase and retirement of common shares	(2,088)			(2,088)
Purchase and retirement of common shares, Shares			(248)
Issuance of common stock in connection with public offering, net of commissions and expenses of $6,200	95,036			95,036
Issuance of common stock in connection with public offering, net of commissions and expenses of $6,200, Shares			9,200
Stock-based compensation	7,139			7,139
NET INCOME (LOSS)	(14,922)					(14,922)
Currency translation adjustments	3,273				3,273
Unrealized gain (loss) on marketable securities	(234)				(234)
Ending Balance at Dec. 31, 2020	$ 398,571			$ 505,123	$ (9,097)	$ (97,455)
Ending Balance, Shares at Dec. 31, 2020			71,738

Summary of Significant Accounting Policies - Summary of Total Net Revenues by Product Line (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disaggregation Of Revenue [Line Items]
Net revenues	$ 171,721	$ 154,605	$ 181,743
Product and Services Revenues [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	166,381	148,073	165,428
Product and Services Revenues [Member] \| Infectious Disease Testing [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	54,227	58,016	56,159
Product and Services Revenues [Member] \| Risk Assessment Testing [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	9,374	12,189	12,058
Product and Services Revenues [Member] \| Cryosurgical Systems [Member]
Disaggregation Of Revenue [Line Items]
Net revenues		7,054	10,767
Product and Services Revenues [Member] \| Genomics [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	37,141	56,200	79,754
Product and Services Revenues [Member] \| Microbiome [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	6,156	7,172	6,690
Product and Services Revenues [Member] \| COVID-19 [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	49,802
Product and Services Revenues [Member] \| Laboratory Services [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	9,564	6,767
Product and Services Revenues [Member] \| Other Product Revenue [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	117	675
Other [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	5,340	6,532	16,315
Other [Member] \| Royalty Income [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	3,432	5,116	9,653
Other [Member] \| Other Non Product Revenues [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	$ 1,908	$ 1,416	$ 6,662

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2020

Income Tax Disclosure [Abstract]

Schedule of Income (Loss) Before Income Tax Expense (Benefit)

Income (loss) before income tax expense consists of the following:

	Years Ended December 31,
	2020			2019		2018
United States	$	(47,995	)	$	3,106	$	(11,728	)
Foreign		44,471			18,225		43,444
	$	(3,524	)	$	21,331	$	31,716

Components of Income Tax Expense (Benefit)

The components of income tax expense are as follows:

	Years Ended December 31,
	2020			2019			2018
Current
Federal	$	—		$	—		$	—
State		(106	)		1,033			155
Foreign		11,896			5,099			12,084
		11,790			6,132			12,239
Deferred
Federal		(20,946	)		3,568			9,200
State		(1,053	)		125			1,011
Foreign		(410	)		(697	)		(919	)
		(22,409	)		2,996			9,292
Decrease in valuation allowance		22,017			(4,453	)		(10,211	)
		(392	)		(1,457	)		(919	)
Total income tax expense	$	11,398		$	4,675		$	11,320

Reconciliation of Statutory United States Federal Income Tax Rate to Domestic Effective Tax Rate

A reconciliation of the statutory United States federal income tax rate to our effective tax rate for each of the years ended December 31, 2020, 2019, and 2018 is as follows:

	2020				2019				2018
Statutory U.S. federal income tax rate		21.0		%		21.0		%		21.0		%
Deemed repatriation tax		—				—				10.9
GILTI tax		—				16.9				22.2
Nondeductible executive compensation		(0.9	)			0.4				4.8
Impact of share-based payment awards		(12.4	)			(5.3	)			0.6
Tax effect of foreign items		(70.7	)			4.5				6.8
State income taxes, net of federal benefit		26.0				4.0				2.8
U.S. and foreign tax credits		34.9				(1.1	)			(1.0	)
Nondeductible transaction costs		(2.8	)			1.6				—
Nondeductible expenses and other		(2.6	)			0.4				(0.2	)
NOL adjustment due to change in GILTI regulations		308.9				—				—
Change in valuation allowance, federal and state		(624.8	)			(20.5	)			(32.2	)
Effective tax rate		(323.4	)	%		21.9		%		35.7		%

Components of Total Deferred Tax Assets (Liabilities)

Significant components of our deferred tax assets (liabilities) as of December 31, 2020 and 2019 are as follows:

	2020			2019
Deferred tax assets (liabilities):
Net operating loss carryforwards	$	31,701		$	9,897
Inventories		1,593			2,002
Capitalized research and development costs		746			1,183
Accruals and reserves currently not deductible		3,200			2,272
Acquired intangible assets		(3,870	)		(3,525	)
Depreciation and amortization		(2,695	)		(1,999	)
Stock-based compensation		1,354			1,777
Tax credit carryforwards		3,354			2,055
Net deferred tax asset		35,383			13,662
Valuation allowance		(36,578	)		(14,561	)
Net deferred tax liability	$	(1,195	)	$	(899	)

Expiry Details of Federal Net Operating Losses Carryforwards

Our Federal NOL carryforwards expire as follows:

Year of Expiration	NOLs
2021 - 2031	$	26,317
2032 - 2037	$	45,072
Non-Expiring		64,865
	$	136,254

Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits

A reconciliation of our unrecognized tax benefits is as follows:

	2020			2019			2018
Balance as of January 1	$	1,308		$	1,676		$	1,663
Additions for tax positions of prior periods		1			4			44
Reductions for tax positions of prior periods		(137	)		(372	)		(31	)
Balance as of December 31	$	1,172		$	1,308		$	1,676

Summary of Significant Accounting Policies - Computations of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Earnings Per Share [Abstract]
NET INCOME (LOSS)	$ (14,922)	$ 16,656	$ 20,396
SHARES USED IN COMPUTING EARNINGS (LOSS) PER SHARE:
Basic	67,505	61,675	61,112
Dilutive effect of stock options, restricted stock, and performance stock units		495	1,420
Diluted	67,505	62,170	62,532
Basic	$ (0.22)	$ 0.27	$ 0.33
Diluted	$ (0.22)	$ 0.27	$ 0.33

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Business Segment Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2020 Segment
Segment Reporting [Abstract]
Number of reportable segments of company	2

Income Taxes - Schedule of Income (Loss) Before Income Tax Expense (Benefit) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest [Abstract]
United States	$ (47,995)	$ 3,106	$ (11,728)
Foreign	44,471	18,225	43,444
Income (loss) before income taxes	$ (3,524)	$ 21,331	$ 31,716

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

The Company - Additional Information (Detail)	12 Months Ended
The Company - Additional Information (Detail)	Dec. 31, 2020 Segment
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Number of Segments of company	2

Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	$ 105,464	$ 77,221
Less accumulated depreciation	(53,604)	(46,882)
Property plant and equipment Net	51,860	30,339
Land [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	1,118	1,118
Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	26,480	23,231
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	36,878	33,568
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	13,024	11,590
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	3,545	2,791
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	$ 24,419	$ 4,923

Leases - Summary of Supplemental Balance Sheet Information Related to Leases (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Operating Leases
Right-of-use assets	$ 4,461	$ 4,996
Current lease liabilities	1,125	1,032
Non-current lease liabilities	3,591	4,206
Total operating lease liabilities	4,716	5,238
Finance Leases
Right-of-use assets	1,312	1,951
Current lease liabilities	517	613
Non-current lease liabilities	895	1,372
Total finance lease liabilities	$ 1,412	$ 1,985

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

Principles of Consolidation and Basis of Presentation

Use of Estimates

Supplemental Cash Flow Information

In 2020, 2019 and 2018, we paid income taxes of $9,263, $10,611 and $17,126, respectively.

As of December 31, 2020, 2019 and 2018, we had accruals for purchases of property and equipment of $802, $660, and $964, respectively.

Investments

The following is a summary of our available-for-sale securities as of December 31, 2020 and 2019:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
December 31, 2020
Guaranteed investment certificates	$	25,132	$	—	$	—		$	25,132
Corporate bonds		71,533		135		(483	)		71,185
Total available-for-sale securities	$	96,665	$	135	$	(483	)	$	96,317
December 31, 2019
Guaranteed investment certificates	$	24,632	$	—	$	—		$	24,632
Corporate bonds		89,525		271		(385	)		89,411
Total available-for-sale securities	$	114,157	$	271	$	(385	)	$	114,043
At December 31, 2020, maturities of our available- for-sale securities were as follows:
Less than one year	$	48,835	$	114	$	(350	)	$	48,599
Greater than one year	$	47,830	$	21	$	(133	)	$	47,718

Fair Value of Financial Instruments

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

The following table represents the change in contingent consideration:

Balance as of January 1, 2019	$	—
Addition related to acquisition (initial measurement)		4,350
Change in fair value during the period		(664	)
Currency translation adjustment		(74	)
Balance as of December 31, 2019		3,612
Addition related to acquisition (initial measurement)		3,440
Payments made during the period		(3,500	)
Change in fair value during the period		(1,099	)
Currency translation adjustment		(2	)
Balance as of December 31, 2020	$	2,451

Accounts Receivable

Inventories

Property, Plant and Equipment

Intangible Assets

Impairment of Long-Lived Assets

Goodwill

Revenue

Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.

We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold.

Service revenues. Service revenues represent microbiome laboratory testing and analytical services. We recognize revenues and satisfy our performance obligation for services rendered.

For certain products or services and customer types, we may require payment before the products are delivered or services are rendered to the customer.

Practical expedients and exemptions. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.

Revenues by product. The following table represents total net revenues by product line:

	Year Ended December 31,
	2020		2019		2018
Infectious disease testing	$	54,227	$	58,016	$	56,159
Risk assessment testing		9,374		12,189		12,058
Cryosurgical systems		—		7,054		10,767
Genomics		37,141		56,200		79,754
Microbiome		6,156		7,172		6,690
COVID-19		49,802		—		—
Laboratory services		9,564		6,767		—
Other product revenue		117		675		—
Net product and service revenues		166,381		148,073		165,428
Royalty income		3,432		5,116		9,653
Other non-product revenues		1,908		1,416		6,662
Other revenues		5,340		6,532		16,315
Net revenues	$	171,721	$	154,605	$	181,743

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:

	Years Ended December 31,
	2020		2019		2018
United States	$	130,835	$	107,279	$	136,847
Europe		12,068		11,752		11,062
Other regions		28,818		35,574		33,834
	$	171,721	$	154,605	$	181,743

Business Combinations and Contingent Consideration

Examples of critical estimates used in valuing certain intangible assets and contingent consideration include:


	•		future expected cash flows from sales and acquired developed technologies;


	•		the acquired company's trade name and customer relationships as well as assumptions about the period of time the acquired trade name and customer relationships will continue to be used in the combined company's portfolio;


	•		the probability of meeting the future events; and

•

discount rates used to determine the present value of estimated future cash flows.

Research and Development

Advertising Expenses

Advertising costs are charged to expense as incurred. During 2020, 2019, and 2018, we incurred $1,126, $468, and $745, respectively, in advertising expenses.

Stock-Based Compensation

Income Taxes

Foreign Currency Translation

Earnings (Loss) Per Share

The computations of basic and diluted earnings (loss) per share are as follows:

	Year ended December 31,
	2020			2019		2018
Net income (loss)	$	(14,922	)	$	16,656	$	20,396
Weighted average shares of common stock outstanding:
Basic		67,505			61,675		61,112
Dilutive effect of stock options, restricted stock, and performance stock units		—			495		1,420
Diluted		67,505			62,170		62,532
Earnings (loss) per share:
Basic	$	(0.22	)	$	0.27	$	0.33
Diluted	$	(0.22	)	$	0.27	$	0.33

Accumulated Other Comprehensive Loss

Recent Accounting Pronouncements

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Income taxes paid	$ 9,263	$ 10,611	$ 17,126
Increase or decrease in allowance for doubtful accounts	941	2,248	(53)
Write-offs against allowance for doubtful accounts	501	11	11
Accruals for purchases of property and equipment	802	660	964
Cash and cash equivalents	160,802	75,715
Fair value of plan assets	2,565	3,519
Deferred revenue	$ 4,811	3,713
Contract with customer payment terms, description	Payment terms differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation.
Advertising expenses	$ 1,126	468	745
Net foreign exchange (losses) gains	(337)	(1,339)	$ 831
Accumulated foreign currency adjustments included in other comprehensive loss amounted	8,749	12,022
Unrealized loss on marketable securities	348	114
Long-term Contract [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred revenue	1,595	1,809
Money Market Fund [Member] \| Level I Instruments [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents	$ 71,489	$ 1,624
Common Stock Options Unvested Restricted Stock and Unvested Performance Units [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of anti-dilutive securities excluded from EPS computation	984	768	291
Up Front Payment Arrangement [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred revenue	$ 3,216	$ 1,904
Customer [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk	11.00%	19.00%
Customer [Member] \| Net Consolidated Revenue [Member] \| Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk		15.00%	24.00%
Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Intangible Assets, Amortization Period (Years)	5 years
Contract with customer payment terms	30 days
Minimum [Member] \| Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	20 years
Minimum [Member] \| Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	2 years
Minimum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	2 years
Minimum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	2 years
Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Intangible Assets, Amortization Period (Years)	15 years
Contract with customer payment terms	120 days
Sales commissions amortization period	1 year
Maximum [Member] \| Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	40 years
Maximum [Member] \| Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	10 years
Maximum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	10 years
Maximum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	10 years

Income Taxes - Components of Total Deferred Tax Assets (Liabilities) (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets (liabilities):
Net operating loss carryforwards	$ 31,701	$ 9,897
Inventories	1,593	2,002
Capitalized research and development costs	746	1,183
Accruals and reserves currently not deductible	3,200	2,272
Acquired intangible assets	(3,870)	(3,525)
Depreciation and amortization	(2,695)	(1,999)
Stock-based compensation	1,354	1,777
Tax credit carryforwards	3,354	2,055
Net deferred tax asset	35,383	13,662
Valuation allowance	(36,578)	(14,561)
Net deferred tax liability	$ (1,195)	$ (899)

Leases - Schedule of Minimum Lease Payments by Period Expected (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Finance Lease Liabilities, Payments, Due [Abstract]
2021	$ 566
2022	566
2023	337
2024	25
2025	4
Total Minimum Finance Lease Payments	1,498
Less: imputed interest	(86)
Present Value of Finance Lease Liabilities	1,412	$ 1,985
Operating Lease Liabilities, Payments Due [Abstract]
2021	1,332
2022	1,315
2023	874
2024	894
2025	520
Thereafter	325
Total Minimum Operating Lease Payments	5,260
Less: imputed interest	(544)
Present Value of Operating Lease Liabilities	$ 4,716	$ 5,238

Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2020

Payables And Accruals [Abstract]

Schedule of Accrued Expenses

	December 31,
	2020		2019
Payroll and related benefits	$	14,769	$	6,088
Professional fees		978		2,769
Other		6,480		5,431
	$	22,227	$	14,288

Sale of Cryosurgical Business

12 Months Ended

Dec. 31, 2020

Discontinued Operations And Disposal Groups [Abstract]

Sale of Cryosurgical Business

4. SALE OF CRYOSURGICAL BUSINESS

On August 16, 2019, we sold all rights and title to the assets necessary to operate our cryosurgical systems line of business to

a third party for $12,000. This business consisted of medical devices used for the removal of benign skin lesions by cryosurgery or freezing. The products were sold in both the professional and OTC markets in North America, Europe, Central and South America and Australia. We also entered into a transition services agreement with CryoConcepts in which both parties agreed to provide certain transition services beginning after the closing. The Company recorded a gain on sale of business of $10,149 reflected in our statement of income for the year ended December 31, 2019. The gain includes the $12,000 of proceeds net of the fair value of the assets sold, which consisted entirely of inventory and fully-depreciated fixed assets, the legal fees associated with the transaction, and a value attributed to the transition services.

Business Combinations - Additional Information (Detail) - USD ($) $ in Thousands				3 Months Ended	12 Months Ended
	Jul. 22, 2020	Nov. 08, 2019	Jan. 04, 2019	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Business acquisition contingent consideration, non-current					$ 2,049	$ 112
Net revenues					171,721	154,605	$ 181,743
Net income (loss)					(14,922)	16,656	$ 20,396
UrSure Inc [Member]
Business Acquisition [Line Items]
Purchase price	$ 3,000
Business acquisition contingent consideration, non-current	$ 28,000
Business combination contingent consideration expected payment period	4 years
Estimated fair value of contingent consideration	$ 3,440				2,451
Acquisition-related costs					393
Net revenues	$ 842
UrSure Inc [Member] \| Developed Technology [Member]
Business Acquisition [Line Items]
Intangible Assets, Amortization Period (Years)	10 years
Diversigen, Inc. [Member]
Business Acquisition [Line Items]
Purchase price		$ 12,000
Business acquisition contingent consideration, non-current					$ 1,500
Acquisition-related costs						1,198
Net revenues						1,046
Business combination contingent consideration expected payment year					2020
Net income (loss)						(47)
Corebiome Inc. and Novosanis NV [Member]
Business Acquisition [Line Items]
Purchase price			$ 13,320
Business acquisition contingent consideration, non-current			$ 32,400
Business combination contingent consideration expected payment period			3 years		1 year
Estimated fair value of contingent consideration			$ 4,350		$ 0	3,612
Acquisition-related costs						639
Net revenues						5,152
Net income (loss)						$ (2,450)
Payment of acquisition-related contingent consideration			$ 3,500	$ 3,500
Corebiome Inc. and Novosanis NV [Member] \| Developed Technology [Member]
Business Acquisition [Line Items]
Intangible Assets, Amortization Period (Years)			10 years

Stockholders' Equity - Summary of Company's Stock Option Activity (Detail) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020 USD ($) $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward
Options, Outstanding, Beginning Balance \| shares	1,193
Options, Granted \| shares	510
Options, Exercised \| shares	(402)
Options, Expired \| shares	(5)
Options, Forfeited \| shares	(64)
Options, Outstanding, Ending Balance \| shares	1,232
Weighted-Average Exercise Price Per Share, Outstanding, Beginning Balance \| $ / shares	$ 10.68
Options, Vested or expected to vest \| shares	1,232
Weighted-Average Exercise Price Per Share, Granted \| $ / shares	$ 7.16
Options, Exercisable \| shares	636
Weighted-Average Exercise Price Per Share, Exercised \| $ / shares	$ 8.03
Weighted-Average Exercise Price Per Share, Expired \| $ / shares	8.73
Weighted-Average Exercise Price Per Share, Forfeited \| $ / shares	10.12
Weighted-Average Exercise Price Per Share, Outstanding, Ending Balance \| $ / shares	10.12
Weighted-Average Exercise Price Per Share, Vested or expected to vest \| $ / shares	10.12
Weighted-Average Exercise Price Per Share, Exercisable \| $ / shares	$ 11.62
Weighted-Average Remaining Contractual Term, Outstanding	6 years 9 months 14 days
Weighted-Average Remaining Contractual Term, Vested or expected to vest	6 years 9 months 14 days
Weighted-Average Remaining Contractual Term, Exercisable	4 years 10 months 13 days
Aggregate Intrinsic Value, Outstanding \| $	$ 2,688
Aggregate Intrinsic Value, Vested or expected to vest \| $	2,688
Aggregate Intrinsic Value, Exercisable \| $	$ 1,034

Stockholders' Equity - Additional Information (Detail) - USD ($)		12 Months Ended
	Jun. 01, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Aug. 05, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grants under the Stock Plan		5,595,000
Amount share repurchase program of common shares					$ 25,000,000
Total cost of common stock purchased and retired		$ 2,088,000	$ 3,712,000	$ 3,592,000
Proceeds from exercise of stock options		3,222,000	196,000	1,701,000
Income tax benefit realized from stock option exercises during period		0	0	0
Total compensation cost		$ 7,139,000	$ 4,057,000	$ 15,237,000
Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock in connection with public offering, net of commissions and expenses of $6,200, Shares	8,000,000
Public offering price per share	$ 11.00
Net offering proceeds after deducting underwriting discount and commission and offering expenses	$ 95,000,000
Over-Allotment Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Underwriters option exercisable period	30 days
Underwriters option to purchase additional shares	$ 1,200,000
Share Repurchase Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased and retired		0	0	0
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent of the fair market value of a share granted as Stock plan price		75.00%
Granted exercise periods		10 years
Vesting period		4 years
Vesting of Options		Options generally vest over four years, with one quarter of the options vesting one year after grant and the remainder vesting on a monthly basis over the next three years.
Weighted-average grant date fair value of stock options granted		$ 2.79	$ 5.19	$ 9.15
Aggregate intrinsic value of options exercised		$ 3,117,000	$ 92,000	$ 2,314,000
Unrecognized compensation expense related to unvested option awards		$ 1,689,000
Expected weighted-average period for recognition of compensation expense related to unvested awards		2 years 7 months 6 days
Proceeds from exercise of stock options		$ 3,222,000	196,000	1,701,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected weighted-average period for recognition of compensation expense related to unvested awards		1 year 8 months 12 days
Total compensation cost		$ 4,094,000	$ 2,979,000	$ 6,357,000
Unrecognized compensation expense related to unvested restricted stock awards		$ 3,697,000
Vesting of restricted shares, withholding and exercise obligations		127,000	76,000	171,000
Restricted shares of common stock, aggregate values		$ 1,219,000	$ 949,000	$ 3,291,000
Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		1 year
Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Performance Based Restricted Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased and retired		121,000	213,000	20,000
Total cost of common stock purchased and retired		$ 869,000	$ 2,763,000	$ 301,000
Total compensation cost		$ 2,153,000	$ (83,000)	$ 6,717,000